Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
Tumors or cancer of the PROSTATE.
Pathological processes involving the PROSTATE or its component tissues.
A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.
Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
Neoplasms containing cyst-like formations or producing mucin or serum.
A malignant epithelial tumor with a glandular organization.
An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.
Tumors or cancer of the SKIN.
A secreted prostate-specific protein which can bind non-polar steroids, cholesterol and a group of small, proline-rich peptides. The protein is specifically found in RATS and comprises three distinct secretoglobin-related subunits referred to as prostatic steroid-binding protein C1, C2 and C3.
Tumors or cancers of the KIDNEY.
Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
The surgical removal of one or both testicles.
An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.
Steroidal compounds in which one or more carbon atoms in the steroid ring system have been substituted with nitrogen atoms.
DNA present in neoplastic tissue.
Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A plant genus in the family ARECACEAE, order Arecales, subclass Arecidae. The fruit or the extract (Permixon) is used for PROSTATIC HYPERPLASIA.
Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.
Inability to empty the URINARY BLADDER with voiding (URINATION).
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A structurally-related family of small, multimeric proteins that are secreted in the mucosa of mammalian epithelial tissues. A variety of proteins are classed under this heading including some secretoglobin subtypes that appear unique to a particular mammalian species, and others whose functions differ between species.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
An orally active synthetic progestational hormone used often in combinations as an oral contraceptive.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Tumors or cancer of the LUNG.
Carrier proteins produced in the Sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. They participate in the transport of androgens. Androgen-binding protein has the same amino acid sequence as SEX HORMONE-BINDING GLOBULIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer located in bone tissue or specific BONES.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Tumors or cancer of the PAROTID GLAND.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
Surgical removal or artificial destruction of gonads.
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
An abnormal concretion occurring mostly in the urinary and biliary tracts, usually composed of mineral salts. Also called stones.
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the ENDOCRINE GLANDS.
Neoplasms composed of more than one type of neoplastic tissue.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
A saclike, glandular diverticulum on each ductus deferens in male vertebrates. It is united with the excretory duct and serves for temporary storage of semen. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Tumors or cancer of the EYE.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Tumors or cancer of the URINARY BLADDER.
Tumors or cancer of the NOSE.
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
Tumors or cancer of the SALIVARY GLANDS.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
An oxidoreductase that catalyzes the conversion of 3-oxo-delta4 steroids into their corresponding 5alpha form. It plays an important role in the conversion of TESTOSTERONE into DIHYDROTESTOSTERONE and PROGESTERONE into DIHYDROPROGESTERONE.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Enzymes that catalyze inversion of the configuration around an asymmetric carbon in a substrate having one (racemase) or more (epimerase) center(s) of asymmetry. (Dorland, 28th ed) EC 5.1.
All the organs involved in reproduction and the formation and release of URINE. It includes the kidneys, ureters, BLADDER; URETHRA, and the organs of reproduction - ovaries, UTERUS; FALLOPIAN TUBES; VAGINA; and CLITORIS in women and the testes; SEMINAL VESICLES; PROSTATE; seminal ducts; and PENIS in men.
A benign epithelial tumor with a glandular organization.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Tumors or cancer of the UTERUS.
Lower urinary tract symptom, such as slow urinary stream, associated with PROSTATIC HYPERPLASIA in older men.
Partial or complete blockage in any part of the URETHRA that can lead to difficulty or inability to empty the URINARY BLADDER. It is characterized by an enlarged, often damaged, bladder with frequent urges to void.
Tumors or cancer of the INTESTINES.
An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
The thick, yellowish-white, viscid fluid secretion of male reproductive organs discharged upon ejaculation. In addition to reproductive organ secretions, it contains SPERMATOZOA and their nutrient plasma.
Symptoms of disorders of the lower urinary tract including frequency, NOCTURIA; urgency, incomplete voiding, and URINARY INCONTINENCE. They are often associated with OVERACTIVE BLADDER; URINARY INCOMPETENCE; and INTERSTITIAL CYSTITIS. Lower urinary tract symptoms in males were traditionally called PROSTATISM.
A tube that transports URINE from the URINARY BLADDER to the outside of the body in both the sexes. It also has a reproductive function in the male by providing a passage for SPERM.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Sweat gland neoplasms are abnormal growths that can be benign or malignant, originating from the sweat glands (eccrine or apocrine) and found anywhere on the skin surface.
A general term for various neoplastic diseases of the lymphoid tissue.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Tumors or cancer of the COLON.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
The mechanical laws of fluid dynamics as they apply to urine transport.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Tumors or cancer of the MANDIBLE.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tartrates are salts or esters of tartaric acid, primarily used in pharmaceutical industry as buffering agents, and in medical laboratories for the precipitation of proteins.
Tumors or cancer of the BILE DUCTS.
Tumors or cancer of the THYMUS GLAND.
One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.
Tumors or cancer of the SPLEEN.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Cancer or tumors of the MAXILLA or upper jaw.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer of the anal gland.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A surgical specialty concerned with the study, diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male. Common urological problems include urinary obstruction, URINARY INCONTINENCE, infections, and UROGENITAL NEOPLASMS.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Pathological processes of the URINARY TRACT in both males and females.
The measurement of an organ in volume, mass, or heaviness.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the DUODENUM.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

Possible suppression of host resistance by estrogen therapy for prostatic cancer.(1/17465)

 (+info)

Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. (2/17465)

Glutathione-S-Transferases (GSTs) comprise a family of isoenzymes that provide protection to mammalian cells against electrophilic metabolites of carcinogens and reactive oxygen species. Previous studies have shown that the CpG-rich promoter region of the pi-class gene GSTP1 is methylated at single restriction sites in the majority of prostate cancers. In order to understand the nature of abnormal methylation of the GSTP1 gene in prostate cancer we undertook a detailed analysis of methylation at 131 CpG sites spanning the promoter and body of the gene. Our results show that DNA methylation is not confined to specific CpG sites in the promoter region of the GSTP1 gene but is extensive throughout the CpG island in prostate cancer cells. Furthermore we found that both alleles are abnormally methylated in this region. In normal prostate tissue, the entire CpG island was unmethylated, but extensive methylation was found outside the island in the body of the gene. Loss of GSTP1 expression correlated with DNA methylation of the CpG island in both prostate cancer cell lines and cancer tissues whereas methylation outside the CpG island in normal prostate tissue appeared to have no effect on gene expression.  (+info)

Using vascular structure for CT-SPECT registration in the pelvis. (3/17465)

The authors outline a method for three-dimensional registration of pelvic CT and 111In-labeled monoclonal antibody capromab pendetide (111In MoAb 7E11.C5) images using 99mTc-labeled red blood cell SPECT data. METHODS: This method of CT-SPECT registration relies on the identification of major blood vessels in the CT and 99mTc SPECT images. The vessels are segmented from the image datasets by outlining them on transverse planar slices using a mouse-based drawing tool. Stacking the transverse outlines provides a three-dimensional representation of the vascular structures. Registration is performed by matching the surfaces of the segmented volumes. Dual isotope acquisition of 111In and 99mTc activities provides precise SPECT-SPECT registration so that registration in three dimensions of the 111In MoAb and CT images is achieved by applying the same transformation obtained from the 99mTc SPECT-CT registration. RESULTS: This method provided accurate registration of pelvic structures and significantly improved interpretation of 111In MoAb 7E11.C5 exams. Furthermore, sites of involvement by prostate cancer suggested by the 111In MoAb examination could be interpreted with the bony and soft tissue (nodal) anatomy seen on CT. CONCLUSION: This method is a general clinical tool for the registration of pelvic CT and SPECT imaging data. There are immediate applications in conformal radiation therapy treatment planning for certain prostate cancer patients.  (+info)

Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. (4/17465)

The aim of the present study was to find out whether increasing malignancy of prostate carcinoma correlates with an overall increase of loss of heterozygosity (LOH), and whether LOH typing of microdissected tumour areas can help to distinguish between multifocal or clonal tumour development. In 47 carcinomas analysed at 25 chromosomal loci, the overall LOH rate was found to be significantly lower in grade 1 areas (2.2%) compared with grade 2 (9.4%) and grade 3 areas (8.3%, P = 0.007). A similar tendency was found for the mean fractional allele loss (FAL, 0.043 for grade 1, 0.2 for grade 2 and 0.23 for grade 3, P = 0.0004). Of 20 tumours (65%) with LOH in several microdissected areas, 13 had identical losses at 1-4 loci within two or three areas, suggesting clonal development of these areas. Markers near RB, DCC, BBC1, TP53 and at D13S325 (13q21-22) showed higher loss rates in grades 2 and 3 (between 25% and 44.4%) compared with grade 1 (0-6.6%). Tumour-suppressor genes (TSGs) near these loci might, thus, be important for tumour progression. TP53 mutations were detected in 27%, but BBC1 mutations in only 7%, of samples with LOH. Evaluation of all 25 loci in every tumour made evident that each prostate cancer has its own pattern of allelic losses.  (+info)

Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. (5/17465)

It was previously shown in the PC-295 xenograft that the number of chromogranin A (CgA)-positive neuroendocrine (NE) cells increased after androgen withdrawal. NE cells did not proliferate and differentiated from G0-phase-arrested cells. Here we further characterized NE differentiation, androgen receptor status, and apoptosis-associated Bcl-2 expression in the PC-295 model after androgen withdrawal to assess the origin of NE cells. PC-295 tumor volumes decreased by 50% in 4 days. Intraperitoneal bromodeoxyuridine (BrdU) incorporation and MIB-1 labeling decreased to 0%, and the apoptosis was maximal at day 4. Androgen receptor expression and prostate-specific antigen (PSA) serum levels decreased rapidly within 2 days. The number of NE cells increased 6-fold at day 4 and 30-fold at day 7. Five and ten percent of the CgA-positive cells were BrdU positive after continuous BrdU labeling for 2 and 4 days, respectively. However, no MIB-1 expression was observed in CgA-positive cells. NE cells expressed the regulated secretory pathway marker secretogranin III but were negative for androgen receptor and Bcl-2. Bcl-2 expression did increase in the non-NE tumor cells. In conclusion, androgen withdrawal leads to a rapid PC-295 tumor regression and a proliferation-independent induction of NE differentiation. The strictly androgen-independent NE cells that were still present after 21 days differentiated mainly from G0-phase-arrested cells.  (+info)

A fluorescent orthotopic bone metastasis model of human prostate cancer. (6/17465)

Here, we report a fluorescent spontaneous bone metastatic model of human prostate cancer developed by surgical orthotopic implantation of green fluorescent protein (GFP)-expressing prostate cancer tissue. Human prostate cancer PC-3 cells were transduced with the pLEIN expression retroviral vector containing the enhanced GFP and neomycin resistance genes. Stable GFP high-expression PC-3 clones were selected in vitro with G418, which were then combined and injected s.c. in nude mice. For metastasis studies, fragments of a single highly fluorescent s.c. growing tumor were implanted by surgical orthotopic implantation in the prostate of a series of nude mice. Subsequent micrometastases and metastases were visualized by GFP fluorescence throughout the skeleton, including the skull, rib, pelvis, femur, and tibia The central nervous system, including the brain and spinal cord, was also involved with tumor, as visualized by GFP fluorescence. Systemic organs, including the lung, plural membrane, liver, kidney, and adrenal gland, also had fluorescent metastases. The metastasis pattern in this model reflects the bone and other metastatic sites of human prostate cancer. Thus, this model should be very useful for the study and development of treatment for metastatic androgen-independent prostate cancer.  (+info)

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. (7/17465)

Prostate cancer development and progression is driven by the accumulation of genetic changes, the nature of which remains incompletely understood To facilitate high-throughput analysis of molecular events taking place in primary, recurrent, and metastat prostate cancer, we constructed a tissue microarray containing small 0.6-mm cylindrical samples acquired from 371 formalin-fixed blocks, including benign prostatic hyperplasia (n = 32) and primary tumors (n = 223), as well as both locally recurrent tumors (n = 54) and metastases (n = 62) from patients with hormone-refractory disease. Fluorescence in situ hybridization (FISH) was applied to the analysis of consecutive tissue microarray sections with probes for five different genes. High-level (> or =3X) amplifications were very rare (<2%) in primary prostate cancers However, in metastases from patients with hormone-refractory disease, amplification of the androgen receptor gene was seen in 22%, MYC in 11%, and Cyclin-D1 in 5% of the cases. In specimens from locally recurrent tumors, the corresponding percentages were 23, 4, and 8%. ERBB2 and NMYC amplifications were never detected at any stage of prostate cancer progression. In conclusion, FISH to tissue microarray sections enables high-throughput analysis of genetic alterations contributing to cancer development and progression. Our results implicate a role for amplification of androgen receptor in hormonal therapy failure and that of MYC in the metastatic progression of human prostate cancer.  (+info)

Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. (8/17465)

Whether oncogenic human papilloma viruses (HPVs) are involved in the pathogenesis of prostate cancers has been a subject of great controversy. To clarify the contradictory results of investigations, with the aim of detecting viral nucleic acids in prostate cancers, we have carried out a comparative quantitation of the HPV16-E6 sequence in 84 prostate specimens. Using single-tube quantitative competitive PCR, we characterized 47 prostate cancers and 37 control tissues of benign prostatic hyperplasia. A subgroup of the prostate tumors (10 of 47; 21%) was detected as having significantly higher copy numbers of HPV16-E6 sequences when compared to the control tissue (1 of 37; 3%), using a cutoff value of 300 copies per 12,500 diploid cells (two-sided Fisher's exact test, P = 0.02). Our results indicate that the oncogenic HPV16 might contribute to the development of a subset of prostate tumors.  (+info)

Castration-resistant prostate cancer (CRPC) is a more advanced form of prostate cancer that no longer responds to treatments that lower levels of male hormones, such as orchiectomy (surgical removal of the testicles) or medical castration with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. Despite these interventions, the cancer continues to progress and grow. This is often due to the development of mechanisms that allow the cancer cells to produce their own male hormones or become less dependent on them for growth and survival. CRPC is a complex and heterogeneous disease with various clinical manifestations and treatment options, which may include chemotherapy, novel hormonal therapies, immunotherapy, and/or radiation therapy.

Prostatic hyperplasia, also known as benign prostatic hyperplasia (BPH), is a noncancerous enlargement of the prostate gland. The prostate gland surrounds the urethra, the tube that carries urine and semen out of the body. When the prostate gland enlarges, it can squeeze or partially block the urethra, causing problems with urination, such as a weak stream, difficulty starting or stopping the flow, and more frequent urination, especially at night. Prostatic hyperplasia is a common condition as men age and does not necessarily lead to cancer. However, it can cause significant discomfort and decreased quality of life if left untreated. Treatment options include medications, minimally invasive procedures, and surgery.

Prostatic neoplasms refer to abnormal growths in the prostate gland, which can be benign or malignant. The term "neoplasm" simply means new or abnormal tissue growth. When it comes to the prostate, neoplasms are often referred to as tumors.

Benign prostatic neoplasms, such as prostate adenomas, are non-cancerous overgrowths of prostate tissue. They usually grow slowly and do not spread to other parts of the body. While they can cause uncomfortable symptoms like difficulty urinating, they are generally not life-threatening.

Malignant prostatic neoplasms, on the other hand, are cancerous growths. The most common type of prostate cancer is adenocarcinoma, which arises from the glandular cells in the prostate. Prostate cancer often grows slowly and may not cause any symptoms for many years. However, some types of prostate cancer can be aggressive and spread quickly to other parts of the body, such as the bones or lymph nodes.

It's important to note that while prostate neoplasms can be concerning, early detection and treatment can significantly improve outcomes for many men. Regular check-ups with a healthcare provider are key to monitoring prostate health and catching any potential issues early on.

Prostatic diseases refer to a range of medical conditions that affect the prostate gland, a small gland that is part of the male reproductive system. The prostate is located below the bladder and surrounds the urethra, the tube that carries urine and semen out of the body. Some common prostatic diseases include:

1. Benign Prostatic Hyperplasia (BPH): This is a non-cancerous enlargement of the prostate gland that can cause difficulties with urination, such as a weak stream, frequent urination, and a feeling of incomplete bladder emptying.
2. Prostatitis: This is an inflammation or infection of the prostate gland that can cause pain, fever, difficulty urinating, and sexual dysfunction.
3. Prostate Cancer: This is a malignant tumor that develops in the prostate gland and can spread to other parts of the body. It is one of the most common types of cancer in men and can often be treated successfully if detected early.
4. Acute Bacterial Prostatitis: This is a sudden and severe infection of the prostate gland that can cause fever, chills, pain in the lower back and genital area, and difficulty urinating.
5. Chronic Bacterial Prostatitis: This is a recurring or persistent bacterial infection of the prostate gland that can cause symptoms similar to chronic pelvic pain syndrome.
6. Chronic Pelvic Pain Syndrome (CPPS): Also known as chronic nonbacterial prostatitis, this condition is characterized by ongoing pain in the pelvic area, often accompanied by urinary and sexual dysfunction. The exact cause of CPPS is not well understood, but it is thought to be related to inflammation or nerve damage in the prostate gland.

The prostate is a small gland that is part of the male reproductive system. Its main function is to produce a fluid that, together with sperm cells from the testicles and fluids from other glands, makes up semen. This fluid nourishes and protects the sperm, helping it to survive and facilitating its movement.

The prostate is located below the bladder and in front of the rectum. It surrounds part of the urethra, the tube that carries urine and semen out of the body. This means that prostate problems can affect urination and sexual function. The prostate gland is about the size of a walnut in adult men.

Prostate health is an important aspect of male health, particularly as men age. Common prostate issues include benign prostatic hyperplasia (BPH), which is an enlarged prostate not caused by cancer, and prostate cancer, which is one of the most common types of cancer in men. Regular check-ups with a healthcare provider can help to detect any potential problems early and improve outcomes.

Prostatic Intraepithelial Neoplasia (PIN) is a term used in pathology to describe the abnormal growth of cells within the lining of the prostate gland's ducts and acini (small sacs that produce and store fluids). PIN is not considered a cancer, but it can be a precursor to prostate cancer.

There are two types of PIN: low-grade and high-grade. Low-grade PIN shows mild to moderate atypia (abnormalities in the cells), while high-grade PIN displays more significant atypia, which resembles prostate cancer. High-grade PIN is often found close to or within areas of prostate cancer, making it a potential indicator of malignancy.

However, not all cases of high-grade PIN progress to cancer, and some men with high-grade PIN may never develop prostate cancer. Nonetheless, the presence of high-grade PIN might prompt further investigation or monitoring to ensure early detection and treatment of any potential cancer development.

Transurethral Resection of Prostate (TURP) is a surgical procedure that involves the removal of the inner part of an enlarged prostate gland using a resectoscope, a tool with a tiny loop of wire at its end that is inserted into the urethra through the penis. The loop of wire is used to cut and remove the excess tissue, which is then washed out of the body. This procedure is typically performed to relieve moderate to severe urinary symptoms caused by an enlarged prostate, such as difficulty in beginning the flow of urine, a weak stream, and frequent urination, especially at night. It is one of the most common surgical procedures for treating benign prostatic hyperplasia (BPH).

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Prostatitis is a medical condition that refers to inflammation of the prostate gland, which can be caused by bacterial or non-bacterial factors. It can present with various symptoms such as pain in the lower abdomen, pelvis, or genital area, difficulty and/or painful urination, ejaculation pain, and flu-like symptoms. Prostatitis can be acute or chronic, and it is important to seek medical attention for proper diagnosis and treatment.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Prostatic secretory proteins are a group of proteins that are produced and secreted by the prostate gland, which is a small gland that is part of the male reproductive system. These proteins play an important role in maintaining the health and function of the reproductive system.

One of the most well-known prostatic secretory proteins is prostate-specific antigen (PSA), which is often used as a biomarker for the early detection and monitoring of prostate cancer. PSA is a protein that is produced by the cells in the prostate gland and is normally found in low levels in the blood. However, when the prostate gland becomes enlarged or cancerous, the levels of PSA in the blood can increase, making it possible to detect these conditions through a simple blood test.

Other prostatic secretory proteins include prostate-specific acid phosphatase (PSAP), prostatein, and prolactin-inducible protein (PIP). These proteins are also produced by the prostate gland and have various functions, such as helping to liquefy semen and protecting sperm from the immune system.

It is important to note that while these proteins can provide valuable information about the health of the prostate gland, they are not foolproof indicators of disease. Other factors, such as age, inflammation, and benign prostatic hyperplasia (BPH), can also affect the levels of these proteins in the blood. Therefore, it is important to consult with a healthcare professional for proper interpretation and follow-up care.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

Acid phosphatase is a type of enzyme that is found in various tissues and organs throughout the body, including the prostate gland, red blood cells, bone, liver, spleen, and kidneys. This enzyme plays a role in several biological processes, such as bone metabolism and the breakdown of molecules like nucleotides and proteins.

Acid phosphatase is classified based on its optimum pH level for activity. Acid phosphatases have an optimal activity at acidic pH levels (below 7.0), while alkaline phosphatases have an optimal activity at basic or alkaline pH levels (above 7.0).

In clinical settings, measuring the level of acid phosphatase in the blood can be useful as a tumor marker for prostate cancer. Elevated acid phosphatase levels may indicate the presence of metastatic prostate cancer or disease progression. However, it is important to note that acid phosphatase is not specific to prostate cancer and can also be elevated in other conditions, such as bone diseases, liver disorders, and some benign conditions. Therefore, acid phosphatase should be interpreted in conjunction with other diagnostic tests and clinical findings for a more accurate diagnosis.

5-alpha Reductase Inhibitors are a class of drugs that block the action of the enzyme 5-alpha reductase, which is responsible for converting testosterone to dihydrotestosterone (DHT). DHT is a more potent form of testosterone that plays a key role in the development and maintenance of male sexual characteristics and is involved in the pathogenesis of benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness).

By inhibiting the action of 5-alpha reductase, these drugs reduce the levels of DHT in the body, which can help to shrink the prostate gland and improve symptoms of BPH such as difficulty urinating, frequent urination, and weak urine stream. They are also used off-label to treat hair loss in men.

Examples of 5-alpha reductase inhibitors include finasteride (Proscar, Propecia) and dutasteride (Avodart). Common side effects of these drugs may include decreased libido, erectile dysfunction, and breast tenderness or enlargement.

Prostate-Specific Antigen (PSA) is a glycoprotein enzyme produced by the epithelial cells of the prostate gland. It is primarily involved in liquefying semen after ejaculation, allowing sperm mobility.

In clinical medicine, PSA is used as a tumor marker, mainly for monitoring the treatment and recurrence of prostate cancer. Elevated levels of PSA can indicate inflammation, infection, benign prostatic hyperplasia (BPH), or prostate cancer. However, it's important to note that an elevated PSA level does not necessarily confirm cancer; further diagnostic tests like digital rectal examination, transrectal ultrasound, and prostate biopsy are often required for definitive diagnosis.

Doctors may also use PSA isoforms or derivatives, such as free PSA, total PSA, and PSA density, to help improve the specificity of cancer detection and differentiate between malignant and benign conditions.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Dihydrotestosterone (DHT) is a sex hormone and androgen that plays a critical role in the development and maintenance of male characteristics, such as facial hair, deep voice, and muscle mass. It is synthesized from testosterone through the action of the enzyme 5-alpha reductase. DHT is essential for the normal development of the male genitalia during fetal development and for the maturation of the sexual organs at puberty.

In addition to its role in sexual development, DHT also contributes to the growth of hair follicles, the health of the prostate gland, and the maintenance of bone density. However, an excess of DHT has been linked to certain medical conditions, such as benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness).

DHT exerts its effects by binding to androgen receptors in various tissues throughout the body. Once bound, DHT triggers a series of cellular responses that regulate gene expression and influence the growth and differentiation of cells. In some cases, these responses can lead to unwanted side effects, such as hair loss or prostate enlargement.

Medications that block the action of 5-alpha reductase, such as finasteride and dutasteride, are sometimes used to treat conditions associated with excess DHT production. These drugs work by reducing the amount of DHT available to bind to androgen receptors, thereby alleviating symptoms and slowing disease progression.

In summary, dihydrotestosterone is a potent sex hormone that plays a critical role in male sexual development and function. While it is essential for normal growth and development, an excess of DHT has been linked to certain medical conditions, such as BPH and androgenetic alopecia. Medications that block the action of 5-alpha reductase are sometimes used to treat these conditions by reducing the amount of DHT available to bind to androgen receptors.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

I'm sorry for any confusion, but "Prostatein" is not a recognized term in medical literature or anatomy. It's possible there may be a misunderstanding or typo in your query. The prostate is a gland in males that is part of the reproductive system. If you have any questions about the prostate or related health concerns, I'd be happy to try and help clarify those.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

A prostatectomy is a surgical procedure where all or part of the prostate gland is removed. This surgery can be performed through various approaches such as open surgery, laparoscopic surgery, or robotic-assisted surgery. The type of prostatectomy performed depends on the reason for the surgery and the patient's individual circumstances.

There are two main types of prostatectomies: radical and simple. A radical prostatectomy is a surgical procedure to remove the entire prostate gland, seminal vesicles, and surrounding lymph nodes. This type of prostatectomy is typically performed as a treatment for prostate cancer.

A simple prostatectomy, on the other hand, involves removing only the inner part of the prostate gland that is causing symptoms such as difficulty urinating or bladder obstruction. Simple prostatectomies are usually performed to alleviate benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland.

Regardless of the type of prostatectomy, potential risks and complications include bleeding, infection, urinary incontinence, erectile dysfunction, and changes in sexual function. It is important for patients to discuss these risks with their healthcare provider before undergoing surgery.

Androgens are a class of hormones that are primarily responsible for the development and maintenance of male sexual characteristics and reproductive function. Testosterone is the most well-known androgen, but other androgens include dehydroepiandrosterone (DHEA), androstenedione, and dihydrotestosterone (DHT).

Androgens are produced primarily by the testes in men and the ovaries in women, although small amounts are also produced by the adrenal glands in both sexes. They play a critical role in the development of male secondary sexual characteristics during puberty, such as the growth of facial hair, deepening of the voice, and increased muscle mass.

In addition to their role in sexual development and function, androgens also have important effects on bone density, mood, and cognitive function. Abnormal levels of androgens can contribute to a variety of medical conditions, including infertility, erectile dysfunction, acne, hirsutism (excessive hair growth), and prostate cancer.

Orchiectomy is a surgical procedure where one or both of the testicles are removed. It is also known as castration. This procedure can be performed for various reasons, including the treatment of testicular cancer, prostate cancer, or other conditions that may affect the testicles. It can also be done to reduce levels of male hormones in the body, such as in the case of transgender women undergoing gender affirming surgery. The specific medical definition may vary slightly depending on the context and the extent of the procedure.

Finasteride is a synthetic 4-azasteroid compound that acts as a specific inhibitor of Type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is a hormonal byproduct thought to be responsible for the development and worsening of benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA), also known as male pattern baldness.

Finasteride is available in two formulations: finasteride 1 mg (Proscar) and finasteride 5 mg (Propecia). Finasteride 1 mg is used to treat BPH, while finasteride 5 mg is used for the treatment of AGA in men. The drug works by reducing the production of DHT, which in turn slows down the progression of BPH and AGA.

It's important to note that finasteride is not approved for use in women or children, and it should be used with caution in men due to potential side effects such as decreased sexual desire, difficulty in achieving an erection, and a decrease in the amount of semen produced.

I'm sorry for any confusion, but "Azasteroids" is not a medical term or concept. The term "azasteroids" is used in the field of chemistry to refer to a class of compounds that are structurally similar to steroids but have an aziridine ring (a three-membered ring containing two carbon atoms and one nitrogen atom) instead of the usual four-membered ring in the steroid structure.

These compounds may have potential applications in various fields, including medicinal chemistry, but they are not a medical concept or diagnosis. If you have any questions related to medical terminology or health concerns, I would be happy to help you with those!

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Androgen receptors (ARs) are a type of nuclear receptor protein that are expressed in various tissues throughout the body. They play a critical role in the development and maintenance of male sexual characteristics and reproductive function. ARs are activated by binding to androgens, which are steroid hormones such as testosterone and dihydrotestosterone (DHT). Once activated, ARs function as transcription factors that regulate gene expression, ultimately leading to various cellular responses.

In the context of medical definitions, androgen receptors can be defined as follows:

Androgen receptors are a type of nuclear receptor protein that bind to androgens, such as testosterone and dihydrotestosterone, and mediate their effects on gene expression in various tissues. They play critical roles in the development and maintenance of male sexual characteristics and reproductive function, and are involved in the pathogenesis of several medical conditions, including prostate cancer, benign prostatic hyperplasia, and androgen deficiency syndromes.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

"Serenoa" is the medical term for a type of palm tree, also known as Saw Palmetto. The fruit of this plant, Serenoa repens, is commonly used in herbal medicine, particularly for treating symptoms associated with an enlarged prostate gland, such as reducing difficulty in urinating. It contains compounds that are thought to have anti-inflammatory and hormonal effects. However, it's important to note that the effectiveness of Serenoa repbs for treating medical conditions is still a subject of ongoing research and debate.

Urinary bladder neck obstruction is a medical condition that refers to a partial or complete blockage at the bladder neck, which is the area where the bladder connects to the urethra. This obstruction can be caused by various factors such as prostate enlargement, bladder tumors, scar tissue, or nerve damage.

The bladder neck obstruction can lead to difficulty in urinating, a weak urine stream, and the need to strain while urinating. In severe cases, it can cause urinary retention, kidney failure, and other complications. Treatment for this condition depends on the underlying cause and may include medications, surgery, or minimally invasive procedures.

Urinary retention is a medical condition in which the bladder cannot empty completely or at all, resulting in the accumulation of urine in the bladder. This can lead to discomfort, pain, and difficulty in passing urine. Urinary retention can be acute (sudden onset) or chronic (long-term). Acute urinary retention is a medical emergency that requires immediate attention, while chronic urinary retention may be managed with medications or surgery. The causes of urinary retention include nerve damage, bladder muscle weakness, prostate gland enlargement, and side effects of certain medications.

Tumor markers are substances that can be found in the body and their presence can indicate the presence of certain types of cancer or other conditions. Biological tumor markers refer to those substances that are produced by cancer cells or by other cells in response to cancer or certain benign (non-cancerous) conditions. These markers can be found in various bodily fluids such as blood, urine, or tissue samples.

Examples of biological tumor markers include:

1. Proteins: Some tumor markers are proteins that are produced by cancer cells or by other cells in response to the presence of cancer. For example, prostate-specific antigen (PSA) is a protein produced by normal prostate cells and in higher amounts by prostate cancer cells.
2. Genetic material: Tumor markers can also include genetic material such as DNA, RNA, or microRNA that are shed by cancer cells into bodily fluids. For example, circulating tumor DNA (ctDNA) is genetic material from cancer cells that can be found in the bloodstream.
3. Metabolites: Tumor markers can also include metabolic products produced by cancer cells or by other cells in response to cancer. For example, lactate dehydrogenase (LDH) is an enzyme that is released into the bloodstream when cancer cells break down glucose for energy.

It's important to note that tumor markers are not specific to cancer and can be elevated in non-cancerous conditions as well. Therefore, they should not be used alone to diagnose cancer but rather as a tool in conjunction with other diagnostic tests and clinical evaluations.

Secretoglobins are a family of small, secreted proteins that are characterized by their unique structure, which includes two conserved cysteine residues and a characteristic pattern of disulfide bonds. They are found in various body fluids such as tears, saliva, and milk, and are believed to play a role in immune response and inflammation. Some secretoglobins have been shown to bind and transport small hydrophobic molecules, while others may function as growth factors or have anti-microbial properties. The specific functions of individual secretoglobins are still being studied and elucidated.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Chlormadinone Acetate is a synthetic progestin, which is a type of female sex hormone. It is used in the treatment of various medical conditions such as endometriosis, uterine fibroids, and abnormal menstrual bleeding. It works by suppressing the natural progesterone produced by the ovaries, thereby preventing the buildup of the lining of the uterus (endometrium). This medication is available in the form of tablets for oral administration.

It's important to note that Chlormadinone Acetate can cause a range of side effects and should only be used under the supervision of a healthcare provider. Additionally, it may interact with other medications, so it's important to inform your doctor about all the medications you are taking before starting this medication.

Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.

There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.

Testosterone is a steroid hormone that belongs to androsten class of hormones. It is primarily secreted by the Leydig cells in the testes of males and, to a lesser extent, by the ovaries and adrenal glands in females. Testosterone is the main male sex hormone and anabolic steroid. It plays a key role in the development of masculine characteristics, such as body hair and muscle mass, and contributes to bone density, fat distribution, red cell production, and sex drive. In females, testosterone contributes to sexual desire and bone health. Testosterone is synthesized from cholesterol and its production is regulated by luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Myeloproliferative disorders (MPDs) are a group of rare, chronic blood cancers that originate from the abnormal proliferation or growth of one or more types of blood-forming cells in the bone marrow. These disorders result in an overproduction of mature but dysfunctional blood cells, which can lead to serious complications such as blood clots, bleeding, and organ damage.

There are several subtypes of MPDs, including:

1. Chronic Myeloid Leukemia (CML): A disorder characterized by the overproduction of mature granulocytes (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CML is caused by a genetic mutation that results in the formation of the BCR-ABL fusion protein, which drives uncontrolled cell growth and division.
2. Polycythemia Vera (PV): A disorder characterized by the overproduction of all three types of blood cells - red blood cells, white blood cells, and platelets - in the bone marrow. This can lead to an increased risk of blood clots, bleeding, and enlargement of the spleen.
3. Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the bone marrow, leading to an increased risk of blood clots and bleeding.
4. Primary Myelofibrosis (PMF): A disorder characterized by the replacement of normal bone marrow tissue with scar tissue, leading to impaired blood cell production and anemia, enlargement of the spleen, and increased risk of infections and bleeding.
5. Chronic Neutrophilic Leukemia (CNL): A rare disorder characterized by the overproduction of neutrophils (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CNL can lead to an increased risk of infections and organ damage.

MPDs are typically treated with a combination of therapies, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the subtype of MPD, the patient's age and overall health, and the presence of any comorbidities.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Androgen-binding protein (ABP) is a protein that binds specifically to androgens, which are hormones such as testosterone that play a role in male sexual development and masculine characteristics. ABP is produced in the Sertoli cells of the testes and helps to regulate the levels of androgens within the testes by storing them and slowly releasing them over time. This is important for maintaining normal sperm production and male reproductive function.

ABP is also found in other tissues, including the prostate gland, where it may play a role in regulating the growth and development of this tissue. Abnormal levels of ABP have been associated with certain medical conditions, such as prostate cancer and infertility.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

Bone neoplasms are abnormal growths or tumors that develop in the bone. They can be benign (non-cancerous) or malignant (cancerous). Benign bone neoplasms do not spread to other parts of the body and are rarely a threat to life, although they may cause problems if they grow large enough to press on surrounding tissues or cause fractures. Malignant bone neoplasms, on the other hand, can invade and destroy nearby tissue and may spread (metastasize) to other parts of the body.

There are many different types of bone neoplasms, including:

1. Osteochondroma - a benign tumor that develops from cartilage and bone
2. Enchondroma - a benign tumor that forms in the cartilage that lines the inside of the bones
3. Chondrosarcoma - a malignant tumor that develops from cartilage
4. Osteosarcoma - a malignant tumor that develops from bone cells
5. Ewing sarcoma - a malignant tumor that develops in the bones or soft tissues around the bones
6. Giant cell tumor of bone - a benign or occasionally malignant tumor that develops from bone tissue
7. Fibrosarcoma - a malignant tumor that develops from fibrous tissue in the bone

The symptoms of bone neoplasms vary depending on the type, size, and location of the tumor. They may include pain, swelling, stiffness, fractures, or limited mobility. Treatment options depend on the type and stage of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

Carcinoma is a type of cancer that develops from epithelial cells, which are the cells that line the inner and outer surfaces of the body. These cells cover organs, glands, and other structures within the body. Carcinomas can occur in various parts of the body, including the skin, lungs, breasts, prostate, colon, and pancreas. They are often characterized by the uncontrolled growth and division of abnormal cells that can invade surrounding tissues and spread to other parts of the body through a process called metastasis. Carcinomas can be further classified based on their appearance under a microscope, such as adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

Parotid neoplasms refer to abnormal growths or tumors in the parotid gland, which is the largest of the salivary glands and is located in front of the ear and extends down the neck. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parotid neoplasms are typically slow-growing, painless masses that may cause facial asymmetry or difficulty in chewing or swallowing if they become large enough to compress surrounding structures. The most common type of benign parotid tumor is a pleomorphic adenoma.

Malignant parotid neoplasms, on the other hand, are more aggressive and can invade nearby tissues and spread to other parts of the body. They may present as rapidly growing masses that are firm or fixed to surrounding structures. Common types of malignant parotid tumors include mucoepidermoid carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma.

The diagnosis of parotid neoplasms typically involves a thorough clinical evaluation, imaging studies such as CT or MRI scans, and fine-needle aspiration biopsy (FNAB) to determine the nature of the tumor. Treatment options depend on the type, size, and location of the neoplasm but may include surgical excision, radiation therapy, and chemotherapy.

Neoplasms of connective and soft tissue are abnormal growths or tumors that develop in the body's supportive tissues, such as cartilage, tendons, ligaments, fascia, and fat. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign connective and soft tissue neoplasms include:
- Lipomas: slow-growing, fatty tumors that develop under the skin.
- Fibromas: firm, benign tumors that develop in connective tissue such as tendons or ligaments.
- Nevi (plural of nevus): benign growths made up of cells called melanocytes, which produce pigment.

Malignant connective and soft tissue neoplasms include:
- Sarcomas: a type of cancer that develops in the body's supportive tissues such as muscle, bone, fat, cartilage, or blood vessels. There are many different types of sarcomas, including liposarcoma (fatty tissue), rhabdomyosarcoma (muscle), and osteosarcoma (bone).
- Desmoid tumors: a rare type of benign tumor that can become aggressive and invade surrounding tissues. While not considered cancerous, desmoid tumors can cause significant morbidity due to their tendency to grow and infiltrate nearby structures.

Connective and soft tissue neoplasms can present with various symptoms depending on their location and size. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis (spread) of the tumor.

Plasma cell neoplasms are a type of cancer that originates from plasma cells, which are a type of white blood cell found in the bone marrow. These cells are responsible for producing antibodies to help fight off infections. When plasma cells become cancerous and multiply out of control, they can form a tumor called a plasmacytoma.

There are two main types of plasma cell neoplasms: solitary plasmacytoma and multiple myeloma. Solitary plasmacytoma is a localized tumor that typically forms in the bone, while multiple myeloma is a systemic disease that affects multiple bones and can cause a variety of symptoms such as bone pain, fatigue, and anemia.

Plasma cell neoplasms are diagnosed through a combination of tests, including blood tests, imaging studies, and bone marrow biopsy. Treatment options depend on the stage and extent of the disease, but may include radiation therapy, chemotherapy, and stem cell transplantation.

Neoplasm invasiveness is a term used in pathology and oncology to describe the aggressive behavior of cancer cells as they invade surrounding tissues and organs. This process involves the loss of cell-to-cell adhesion, increased motility and migration, and the ability of cancer cells to degrade the extracellular matrix (ECM) through the production of enzymes such as matrix metalloproteinases (MMPs).

Invasive neoplasms are cancers that have spread beyond the original site where they first developed and have infiltrated adjacent tissues or structures. This is in contrast to non-invasive or in situ neoplasms, which are confined to the epithelial layer where they originated and have not yet invaded the underlying basement membrane.

The invasiveness of a neoplasm is an important prognostic factor in cancer diagnosis and treatment, as it can indicate the likelihood of metastasis and the potential effectiveness of various therapies. In general, more invasive cancers are associated with worse outcomes and require more aggressive treatment approaches.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Appendiceal neoplasms refer to various types of tumors that can develop in the appendix, a small tube-like structure attached to the large intestine. These neoplasms can be benign or malignant and can include:

1. Adenomas: These are benign tumors that arise from the glandular cells lining the appendix. They are usually slow-growing and may not cause any symptoms.
2. Carcinoids: These are neuroendocrine tumors that arise from the hormone-producing cells in the appendix. They are typically small and slow-growing, but some can be aggressive and spread to other parts of the body.
3. Mucinous neoplasms: These are tumors that produce mucin, a slippery substance that can cause the appendix to become distended and filled with mucus. They can be low-grade (less aggressive) or high-grade (more aggressive) and may spread to other parts of the abdomen.
4. Adenocarcinomas: These are malignant tumors that arise from the glandular cells lining the appendix. They are relatively rare but can be aggressive and spread to other parts of the body.
5. Pseudomyxoma peritonei: This is a condition in which mucin produced by an appendiceal neoplasm leaks into the abdominal cavity, causing a jelly-like accumulation of fluid and tissue. It can be caused by both benign and malignant tumors.

Treatment for appendiceal neoplasms depends on the type and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, or radiation therapy.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

Castration is a surgical procedure to remove the testicles in males or ovaries in females. In males, it is also known as orchiectomy. This procedure results in the inability to produce sex hormones and gametes (sperm in men and eggs in women), and can be done for various reasons such as medical treatment for certain types of cancer, to reduce sexual urges in individuals with criminal tendencies, or as a form of birth control in animals.

Urethral neoplasms refer to abnormal growths or tumors in the urethra, which is the tube that carries urine from the bladder out of the body. These growths can be benign (non-cancerous) or malignant (cancerous).

Benign urethral neoplasms may include conditions such as urethral polyps or papillomas, which are usually not life-threatening and can often be removed with surgery.

Malignant urethral neoplasms, on the other hand, are cancerous tumors that can invade surrounding tissues and spread to other parts of the body. These include urethral carcinomas, which can be further classified into different types such as squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma, depending on the type of cells involved.

Urethral neoplasms are relatively rare, but when they do occur, they can cause a variety of symptoms such as difficulty urinating, blood in the urine, pain during urination or sexual intercourse, and discharge from the urethra. Treatment options depend on the type, location, and stage of the neoplasm, and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

"Calculi" is a medical term that refers to abnormal concretions or hard masses formed within the body, usually in hollow organs or cavities. These masses are typically composed of minerals such as calcium oxalate, calcium phosphate, or magnesium ammonium phosphate, and can vary in size from tiny granules to large stones. The plural form of the Latin word "calculus" (meaning "pebble"), calculi are commonly known as "stones." They can occur in various locations within the body, including the kidneys, gallbladder, urinary bladder, and prostate gland. The presence of calculi can cause a range of symptoms, such as pain, obstruction, infection, or inflammation, depending on their size, location, and composition.

Adrenergic alpha-1 receptor antagonists, also known as alpha-blockers, are a class of medications that block the effects of the neurotransmitter norepinephrine at alpha-1 receptors. These receptors are found in various tissues throughout the body, including the smooth muscle of blood vessels, the bladder, and the eye.

When norepinephrine binds to alpha-1 receptors, it causes smooth muscle to contract, leading to vasoconstriction (constriction of blood vessels), increased blood pressure, and other effects. By blocking these receptors, alpha-blockers can cause relaxation of smooth muscle, leading to vasodilation (expansion of blood vessels), decreased blood pressure, and other effects.

Alpha-blockers are used in the treatment of various medical conditions, including hypertension (high blood pressure), benign prostatic hyperplasia (enlarged prostate), and pheochromocytoma (a rare tumor of the adrenal gland). Examples of alpha-blockers include doxazosin, prazosin, and terazosin.

It's important to note that while alpha-blockers can be effective in treating certain medical conditions, they can also have side effects, such as dizziness, lightheadedness, and orthostatic hypotension (a sudden drop in blood pressure when standing up). As with any medication, it's important to use alpha-blockers under the guidance of a healthcare provider.

Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.

Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.

While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.

Testicular neoplasms are abnormal growths or tumors in the testicle that can be benign (non-cancerous) or malignant (cancerous). They are a type of genitourinary cancer, which affects the reproductive and urinary systems. Testicular neoplasms can occur in men of any age but are most commonly found in young adults between the ages of 15 and 40.

Testicular neoplasms can be classified into two main categories: germ cell tumors and non-germ cell tumors. Germ cell tumors, which arise from the cells that give rise to sperm, are further divided into seminomas and non-seminomas. Seminomas are typically slow-growing and have a good prognosis, while non-seminomas tend to grow more quickly and can spread to other parts of the body.

Non-germ cell tumors are less common than germ cell tumors and include Leydig cell tumors, Sertoli cell tumors, and lymphomas. These tumors can have a variety of clinical behaviors, ranging from benign to malignant.

Testicular neoplasms often present as a painless mass or swelling in the testicle. Other symptoms may include a feeling of heaviness or discomfort in the scrotum, a dull ache in the lower abdomen or groin, and breast enlargement (gynecomastia).

Diagnosis typically involves a physical examination, imaging studies such as ultrasound or CT scan, and blood tests to detect tumor markers. Treatment options depend on the type and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular self-examinations of the testicles are recommended for early detection and improved outcomes.

Radiation-induced neoplasms are a type of cancer or tumor that develops as a result of exposure to ionizing radiation. Ionizing radiation is radiation with enough energy to remove tightly bound electrons from atoms or molecules, leading to the formation of ions. This type of radiation can damage DNA and other cellular structures, which can lead to mutations and uncontrolled cell growth, resulting in the development of a neoplasm.

Radiation-induced neoplasms can occur after exposure to high levels of ionizing radiation, such as that received during radiation therapy for cancer treatment or from nuclear accidents. The risk of developing a radiation-induced neoplasm depends on several factors, including the dose and duration of radiation exposure, the type of radiation, and the individual's genetic susceptibility to radiation-induced damage.

Radiation-induced neoplasms can take many years to develop after initial exposure to ionizing radiation, and they often occur at the site of previous radiation therapy. Common types of radiation-induced neoplasms include sarcomas, carcinomas, and thyroid cancer. It is important to note that while ionizing radiation can increase the risk of developing cancer, the overall risk is still relatively low, especially when compared to other well-established cancer risk factors such as smoking and exposure to certain chemicals.

There is no medical definition for "dog diseases" as it is too broad a term. However, dogs can suffer from various health conditions and illnesses that are specific to their species or similar to those found in humans. Some common categories of dog diseases include:

1. Infectious Diseases: These are caused by viruses, bacteria, fungi, or parasites. Examples include distemper, parvovirus, kennel cough, Lyme disease, and heartworms.
2. Hereditary/Genetic Disorders: Some dogs may inherit certain genetic disorders from their parents. Examples include hip dysplasia, elbow dysplasia, progressive retinal atrophy (PRA), and degenerative myelopathy.
3. Age-Related Diseases: As dogs age, they become more susceptible to various health issues. Common age-related diseases in dogs include arthritis, dental disease, cancer, and cognitive dysfunction syndrome (CDS).
4. Nutritional Disorders: Malnutrition or improper feeding can lead to various health problems in dogs. Examples include obesity, malnutrition, and vitamin deficiencies.
5. Environmental Diseases: These are caused by exposure to environmental factors such as toxins, allergens, or extreme temperatures. Examples include heatstroke, frostbite, and toxicities from ingesting harmful substances.
6. Neurological Disorders: Dogs can suffer from various neurological conditions that affect their nervous system. Examples include epilepsy, intervertebral disc disease (IVDD), and vestibular disease.
7. Behavioral Disorders: Some dogs may develop behavioral issues due to various factors such as anxiety, fear, or aggression. Examples include separation anxiety, noise phobias, and resource guarding.

It's important to note that regular veterinary care, proper nutrition, exercise, and preventative measures can help reduce the risk of many dog diseases.

Endocrine gland neoplasms refer to abnormal growths (tumors) that develop in the endocrine glands. These glands are responsible for producing hormones, which are chemical messengers that regulate various functions and processes in the body. Neoplasms can be benign or malignant (cancerous). Benign neoplasms tend to grow slowly and do not spread to other parts of the body. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to distant sites.

Endocrine gland neoplasms can occur in any of the endocrine glands, including:

1. Pituitary gland: located at the base of the brain, it produces several hormones that regulate growth and development, as well as other bodily functions.
2. Thyroid gland: located in the neck, it produces thyroid hormones that regulate metabolism and calcium balance.
3. Parathyroid glands: located near the thyroid gland, they produce parathyroid hormone that regulates calcium levels in the blood.
4. Adrenal glands: located on top of each kidney, they produce hormones such as adrenaline, cortisol, and aldosterone that regulate stress response, metabolism, and blood pressure.
5. Pancreas: located behind the stomach, it produces insulin and glucagon, which regulate blood sugar levels, and digestive enzymes that help break down food.
6. Pineal gland: located in the brain, it produces melatonin, a hormone that regulates sleep-wake cycles.
7. Gonads (ovaries and testicles): located in the pelvis (ovaries) and scrotum (testicles), they produce sex hormones such as estrogen, progesterone, and testosterone that regulate reproductive function and secondary sexual characteristics.

Endocrine gland neoplasms can cause various symptoms depending on the type and location of the tumor. For example, a pituitary gland neoplasm may cause headaches, vision problems, or hormonal imbalances, while an adrenal gland neoplasm may cause high blood pressure, weight gain, or mood changes.

Diagnosis of endocrine gland neoplasms typically involves a combination of medical history, physical examination, imaging studies such as CT or MRI scans, and laboratory tests to measure hormone levels. Treatment options may include surgery, radiation therapy, chemotherapy, or hormonal therapy, depending on the type and stage of the tumor.

Neoplasms are abnormal growths of cells or tissues in the body that can be benign (non-cancerous) or malignant (cancerous). When referring to "Complex and Mixed Neoplasms," it is typically used in the context of histopathology, where it describes tumors with a mixture of different types of cells or growth patterns.

A complex neoplasm usually contains areas with various architectural patterns, cell types, or both, making its classification challenging. It may require extensive sampling and careful examination to determine its nature and behavior. These neoplasms can be either benign or malignant, depending on the specific characteristics of the tumor cells and their growth pattern.

A mixed neoplasm, on the other hand, is a tumor that contains more than one type of cell or tissue component, often arising from different germ layers (the three primary layers of embryonic development: ectoderm, mesoderm, and endoderm). A common example of a mixed neoplasm is a teratoma, which can contain tissues derived from all three germ layers, such as skin, hair, teeth, bone, and muscle. Mixed neoplasms can also be benign or malignant, depending on the specific components of the tumor.

It's important to note that the classification and behavior of complex and mixed neoplasms can vary significantly based on their location in the body, cellular composition, and other factors. Accurate diagnosis typically requires a thorough examination by an experienced pathologist and may involve additional tests, such as immunohistochemistry or molecular analysis, to determine the appropriate treatment and management strategies.

Gastrointestinal (GI) neoplasms refer to abnormal growths in the gastrointestinal tract, which can be benign or malignant. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus.

Benign neoplasms are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They can sometimes be removed completely and may not cause any further health problems.

Malignant neoplasms, on the other hand, are cancerous growths that can invade nearby tissues and organs and spread to other parts of the body through the bloodstream or lymphatic system. These types of neoplasms can be life-threatening if not diagnosed and treated promptly.

GI neoplasms can cause various symptoms, including abdominal pain, bloating, changes in bowel habits, nausea, vomiting, weight loss, and anemia. The specific symptoms may depend on the location and size of the neoplasm.

There are many types of GI neoplasms, including adenocarcinomas, gastrointestinal stromal tumors (GISTs), lymphomas, and neuroendocrine tumors. The diagnosis of GI neoplasms typically involves a combination of medical history, physical examination, imaging studies, and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.

Doxazosin is an antihypertensive drug, which belongs to the class of medications called alpha-1 receptor blockers. It works by relaxing the muscles in the blood vessels, which helps to lower blood pressure and improve blood flow. Doxazosin is primarily used to treat high blood pressure (hypertension) and benign prostatic hyperplasia (BPH), a condition characterized by an enlarged prostate gland that can cause urinary symptoms such as difficulty in beginning the flow of urine, weak stream, and frequent urination.

The medical definition of Doxazosin is:

Doxazosin mesylate - A selective alpha-1 adrenergic receptor blocker used in the treatment of hypertension and benign prostatic hyperplasia (BPH). It works by relaxing the smooth muscle in blood vessels, which lowers blood pressure and improves blood flow. Doxazosin may also be used off-label for other indications such as Raynaud's phenomenon or painful bladder syndrome. The drug is available in oral tablet form and is typically taken once daily. Common side effects include dizziness, lightheadedness, and headache.

Pancreatic ductal carcinoma (PDC) is a specific type of cancer that forms in the ducts that carry digestive enzymes out of the pancreas. It's the most common form of exocrine pancreatic cancer, making up about 90% of all cases.

The symptoms of PDC are often vague and can include abdominal pain, jaundice (yellowing of the skin and eyes), unexplained weight loss, and changes in bowel movements. These symptoms can be similar to those caused by other less serious conditions, which can make diagnosis difficult.

Pancreatic ductal carcinoma is often aggressive and difficult to treat. The prognosis for PDC is generally poor, with a five-year survival rate of only about 9%. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches. However, because PDC is often not detected until it has advanced, treatment is frequently focused on palliative care to relieve symptoms and improve quality of life.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

A neoplasm of vascular tissue is an abnormal growth or mass of cells in the blood vessels or lymphatic vessels. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms, such as hemangiomas and lymphangiomas, are typically not harmful and may not require treatment. However, they can cause symptoms if they grow large enough to press on nearby organs or tissues. Malignant neoplasms, such as angiosarcomas, are cancerous and can invade and destroy surrounding tissue, as well as spread (metastasize) to other parts of the body. Treatment for vascular tissue neoplasms depends on the type, size, location, and stage of the growth, and may include surgery, radiation therapy, chemotherapy, or a combination of these.

The seminal vesicles are a pair of glands located in the male reproductive system, posterior to the urinary bladder and superior to the prostate gland. They are approximately 5 cm long and have a convoluted structure with many finger-like projections called infoldings. The primary function of seminal vesicles is to produce and secrete a significant portion of the seminal fluid, which makes up the bulk of semen along with spermatozoa from the testes and fluids from the prostate gland and bulbourethral glands.

The secretion of the seminal vesicles is rich in fructose, which serves as an energy source for sperm, as well as various proteins, enzymes, vitamins, and minerals that contribute to maintaining the optimal environment for sperm survival, nourishment, and transport. During sexual arousal and ejaculation, the smooth muscles in the walls of the seminal vesicles contract, forcing the stored secretion into the urethra, where it mixes with other fluids before being expelled from the body as semen.

Eye neoplasms, also known as ocular tumors or eye cancer, refer to abnormal growths of tissue in the eye. These growths can be benign (non-cancerous) or malignant (cancerous). Eye neoplasms can develop in various parts of the eye, including the eyelid, conjunctiva, cornea, iris, ciliary body, choroid, retina, and optic nerve.

Benign eye neoplasms are typically slow-growing and do not spread to other parts of the body. They may cause symptoms such as vision changes, eye pain, or a noticeable mass in the eye. Treatment options for benign eye neoplasms include monitoring, surgical removal, or radiation therapy.

Malignant eye neoplasms, on the other hand, can grow and spread rapidly to other parts of the body. They may cause symptoms such as vision changes, eye pain, floaters, or flashes of light. Treatment options for malignant eye neoplasms depend on the type and stage of cancer but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

It is important to note that early detection and treatment of eye neoplasms can improve outcomes and prevent complications. Regular eye exams with an ophthalmologist are recommended for early detection and prevention of eye diseases, including eye neoplasms.

Carcinoma, acinar cell is a type of pancreatic cancer that originates in the acinar cells of the pancreas. The acinar cells are responsible for producing digestive enzymes. This type of cancer is relatively rare and accounts for less than 5% of all pancreatic cancers. It typically presents with symptoms such as abdominal pain, weight loss, and jaundice. Treatment options may include surgery, chemotherapy, and radiation therapy.

Urinary Bladder Neoplasms are abnormal growths or tumors in the urinary bladder, which can be benign (non-cancerous) or malignant (cancerous). Malignant neoplasms can be further classified into various types of bladder cancer, such as urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. These malignant tumors often invade surrounding tissues and organs, potentially spreading to other parts of the body (metastasis), which can lead to serious health consequences if not detected and treated promptly and effectively.

Nose neoplasms refer to abnormal growths or tumors in the nasal cavity or paranasal sinuses. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and have the potential to metastasize.

Nose neoplasms can cause various symptoms such as nasal congestion, nosebleeds, difficulty breathing through the nose, loss of smell, facial pain or numbness, and visual changes if they affect the eye. The diagnosis of nose neoplasms usually involves a combination of physical examination, imaging studies (such as CT or MRI scans), and biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Urination disorders, also known as lower urinary tract symptoms (LUTS), refer to a range of clinical conditions that affect the bladder and urethra, resulting in abnormalities in the storage, transportation, and evacuation of urine. These disorders can be categorized into voiding symptoms, such as hesitancy, straining, slow stream, intermittency, and terminal dribble; and storage symptoms, including frequency, urgency, nocturia, and urge incontinence.

The causes of urination disorders are diverse, encompassing congenital abnormalities, neurological conditions, infections, inflammation, medications, and age-related changes. Common underlying pathologies include bladder overactivity, detrusor muscle instability, underactive bladder, and obstruction of the urethra.

Urination disorders can significantly impact an individual's quality of life, causing physical discomfort, sleep disturbances, emotional distress, and social isolation. Accurate diagnosis and appropriate management require a comprehensive assessment of the patient's medical history, physical examination, urinalysis, and urodynamic studies. Treatment options may include behavioral modifications, pelvic floor exercises, bladder training, medications, neuromodulation, and surgical interventions.

Salivary gland neoplasms refer to abnormal growths or tumors that develop in the salivary glands. These glands are responsible for producing saliva, which helps in digestion, lubrication of food and maintaining oral health. Salivary gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms are slow-growing and typically do not spread to other parts of the body. They may cause symptoms such as swelling, painless lumps, or difficulty swallowing if they grow large enough to put pressure on surrounding tissues.

Malignant neoplasms, on the other hand, can be aggressive and have the potential to invade nearby structures and metastasize (spread) to distant organs. Symptoms of malignant salivary gland neoplasms may include rapid growth, pain, numbness, or paralysis of facial nerves.

Salivary gland neoplasms can occur in any of the major salivary glands (parotid, submandibular, and sublingual glands) or in the minor salivary glands located throughout the mouth and throat. The exact cause of these neoplasms is not fully understood, but risk factors may include exposure to radiation, certain viral infections, and genetic predisposition.

Immunoenzyme techniques are a group of laboratory methods used in immunology and clinical chemistry that combine the specificity of antibody-antigen reactions with the sensitivity and amplification capabilities of enzyme reactions. These techniques are primarily used for the detection, quantitation, or identification of various analytes (such as proteins, hormones, drugs, viruses, or bacteria) in biological samples.

In immunoenzyme techniques, an enzyme is linked to an antibody or antigen, creating a conjugate. This conjugate then interacts with the target analyte in the sample, forming an immune complex. The presence and amount of this immune complex can be visualized or measured by detecting the enzymatic activity associated with it.

There are several types of immunoenzyme techniques, including:

1. Enzyme-linked Immunosorbent Assay (ELISA): A widely used method for detecting and quantifying various analytes in a sample. In ELISA, an enzyme is attached to either the capture antibody or the detection antibody. After the immune complex formation, a substrate is added that reacts with the enzyme, producing a colored product that can be measured spectrophotometrically.
2. Immunoblotting (Western blot): A method used for detecting specific proteins in a complex mixture, such as a protein extract from cells or tissues. In this technique, proteins are separated by gel electrophoresis and transferred to a membrane, where they are probed with an enzyme-conjugated antibody directed against the target protein.
3. Immunohistochemistry (IHC): A method used for detecting specific antigens in tissue sections or cells. In IHC, an enzyme-conjugated primary or secondary antibody is applied to the sample, and the presence of the antigen is visualized using a chromogenic substrate that produces a colored product at the site of the antigen-antibody interaction.
4. Immunofluorescence (IF): A method used for detecting specific antigens in cells or tissues by employing fluorophore-conjugated antibodies. The presence of the antigen is visualized using a fluorescence microscope.
5. Enzyme-linked immunosorbent assay (ELISA): A method used for detecting and quantifying specific antigens or antibodies in liquid samples, such as serum or culture supernatants. In ELISA, an enzyme-conjugated detection antibody is added after the immune complex formation, and a substrate is added that reacts with the enzyme to produce a colored product that can be measured spectrophotometrically.

These techniques are widely used in research and diagnostic laboratories for various applications, including protein characterization, disease diagnosis, and monitoring treatment responses.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

Adenocarcinoma, papillary is a type of cancer that begins in the glandular cells and grows in a finger-like projection (called a papilla). This type of cancer can occur in various organs, including the lungs, pancreas, thyroid, and female reproductive system. The prognosis and treatment options for papillary adenocarcinoma depend on several factors, such as the location and stage of the tumor, as well as the patient's overall health. It is important to consult with a healthcare professional for an accurate diagnosis and personalized treatment plan.

Carcinoma, papillary is a type of cancer that begins in the cells that line the glandular structures or the lining of organs. In a papillary carcinoma, the cancerous cells grow and form small finger-like projections, called papillae, within the tumor. This type of cancer most commonly occurs in the thyroid gland, but can also be found in other organs such as the lung, breast, and kidney. Papillary carcinoma of the thyroid gland is usually slow-growing and has a good prognosis, especially when it is diagnosed at an early stage.

Neoplasms in muscle tissue refer to abnormal and excessive growths of muscle cells that can be benign or malignant. These growths can arise from any of the three types of muscle tissue: skeletal, cardiac, or smooth muscle. Neoplasms in muscle tissue are classified based on their origin, behavior, and histological features.

Benign neoplasms in muscle tissue include leiomyomas (smooth muscle), rhabdomyomas (skeletal muscle), and myxomas (cardiac muscle). These tumors are usually slow-growing and do not invade surrounding tissues or spread to other parts of the body.

Malignant neoplasms in muscle tissue, also known as sarcomas, include leiomyosarcoma (smooth muscle), rhabdomyosarcoma (skeletal muscle), and angiosarcoma (cardiac muscle). These tumors are aggressive, invasive, and have the potential to metastasize to other parts of the body.

Symptoms of neoplasms in muscle tissue depend on their location, size, and type. They may include a painless or painful mass, weakness, fatigue, weight loss, and difficulty swallowing or breathing. Treatment options for neoplasms in muscle tissue include surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the type, stage, location, and patient's overall health condition.

Neoplasms are abnormal growths of cells or tissues that serve no purpose and can be benign (non-cancerous) or malignant (cancerous). Glandular and epithelial neoplasms refer to specific types of tumors that originate from the glandular and epithelial tissues, respectively.

Glandular neoplasms arise from the glandular tissue, which is responsible for producing and secreting substances such as hormones, enzymes, or other fluids. These neoplasms can be further classified into adenomas (benign) and adenocarcinomas (malignant).

Epithelial neoplasms, on the other hand, develop from the epithelial tissue that lines the outer surfaces of organs and the inner surfaces of cavities. These neoplasms can also be benign or malignant and are classified as papillomas (benign) and carcinomas (malignant).

It is important to note that while both glandular and epithelial neoplasms can become cancerous, not all of them do. However, if they do, the malignant versions can invade surrounding tissues and spread to other parts of the body, making them potentially life-threatening.

Cholestenone 5 alpha-reductase is an enzyme that plays a role in the conversion of cholesterol and other steroid hormones in the body. Specifically, it catalyzes the reduction of 5,7-dihydroxycholest-4-en-3-one (also known as cholestenone) to 5α-androstan-3α,17β-diol, which is a precursor to the male sex hormone testosterone.

This enzyme is found in various tissues throughout the body, including the prostate gland, skin, and liver. In the prostate gland, 5 alpha-reductase helps regulate the growth and function of the gland by converting testosterone to dihydrotestosterone (DHT), a more potent form of the hormone.

Inhibitors of 5 alpha-reductase are sometimes used as medications to treat conditions such as benign prostatic hyperplasia (BPH) and male pattern baldness, as reducing DHT levels can help alleviate symptoms associated with these conditions.

Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.

These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.

Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.

Racemases and epimerases are two types of enzymes that are involved in the modification of the stereochemistry of molecules, particularly amino acids and sugars. Here is a brief definition for each:

1. Racemases: These are enzymes that catalyze the interconversion of D- and L-stereoisomers of amino acids or other chiral compounds. They do this by promoting the conversion of one stereoisomer to its mirror image, resulting in a racemic mixture (a 1:1 mixture of two enantiomers). Racemases are important in various biological processes, such as the biosynthesis of some amino acids and the degradation of certain carbohydrates.

Example: Alanine racemase is an enzyme that catalyzes the conversion of L-alanine to D-alanine, which is essential for bacterial cell wall biosynthesis.

2. Epimerases: These are enzymes that convert one stereoisomer (epimer) of a chiral compound into another stereoisomer by changing the configuration at a single asymmetric carbon atom while keeping the rest of the molecule unchanged. Unlike racemases, epimerases do not produce racemic mixtures but rather create specific stereoisomers.

Example: Glucose-1-phosphate epimerase is an enzyme that converts glucose-1-phosphate to galactose-1-phosphate during the Leloir pathway, which is the primary metabolic route for lactose digestion in mammals.

Both racemases and epimerases play crucial roles in various biochemical processes, including the synthesis and degradation of essential molecules like amino acids and carbohydrates.

The urogenital system is a part of the human body that includes the urinary and genital systems. The urinary system consists of the kidneys, ureters, bladder, and urethra, which work together to produce, store, and eliminate urine. On the other hand, the genital system, also known as the reproductive system, is responsible for the production, development, and reproduction of offspring. In males, this includes the testes, epididymis, vas deferens, seminal vesicles, prostate gland, bulbourethral glands, and penis. In females, it includes the ovaries, fallopian tubes, uterus, vagina, mammary glands, and external genitalia.

The urogenital system is closely related anatomically and functionally. For example, in males, the urethra serves as a shared conduit for both urine and semen, while in females, the urethra and vagina are separate but adjacent structures. Additionally, some organs, such as the prostate gland in males and the Skene's glands in females, have functions that overlap between the urinary and genital systems.

Disorders of the urogenital system can affect both the urinary and reproductive functions, leading to a range of symptoms such as pain, discomfort, infection, and difficulty with urination or sexual activity. Proper care and maintenance of the urogenital system are essential for overall health and well-being.

An adenoma is a benign (noncancerous) tumor that develops from glandular epithelial cells. These types of cells are responsible for producing and releasing fluids, such as hormones or digestive enzymes, into the surrounding tissues. Adenomas can occur in various organs and glands throughout the body, including the thyroid, pituitary, adrenal, and digestive systems.

Depending on their location, adenomas may cause different symptoms or remain asymptomatic. Some common examples of adenomas include:

1. Colorectal adenoma (also known as a polyp): These growths occur in the lining of the colon or rectum and can develop into colorectal cancer if left untreated. Regular screenings, such as colonoscopies, are essential for early detection and removal of these polyps.
2. Thyroid adenoma: This type of adenoma affects the thyroid gland and may result in an overproduction or underproduction of hormones, leading to conditions like hyperthyroidism (overactive thyroid) or hypothyroidism (underactive thyroid).
3. Pituitary adenoma: These growths occur in the pituitary gland, which is located at the base of the brain and controls various hormonal functions. Depending on their size and location, pituitary adenomas can cause vision problems, headaches, or hormonal imbalances that affect growth, reproduction, and metabolism.
4. Liver adenoma: These rare benign tumors develop in the liver and may not cause any symptoms unless they become large enough to press on surrounding organs or structures. In some cases, liver adenomas can rupture and cause internal bleeding.
5. Adrenal adenoma: These growths occur in the adrenal glands, which are located above the kidneys and produce hormones that regulate stress responses, metabolism, and blood pressure. Most adrenal adenomas are nonfunctioning, meaning they do not secrete excess hormones. However, functioning adrenal adenomas can lead to conditions like Cushing's syndrome or Conn's syndrome, depending on the type of hormone being overproduced.

It is essential to monitor and manage benign tumors like adenomas to prevent potential complications, such as rupture, bleeding, or hormonal imbalances. Treatment options may include surveillance with imaging studies, medication to manage hormonal issues, or surgical removal of the tumor in certain cases.

A needle biopsy is a medical procedure in which a thin, hollow needle is used to remove a small sample of tissue from a suspicious or abnormal area of the body. The tissue sample is then examined under a microscope to check for cancer cells or other abnormalities. Needle biopsies are often used to diagnose lumps or masses that can be felt through the skin, but they can also be guided by imaging techniques such as ultrasound, CT scan, or MRI to reach areas that cannot be felt. There are several types of needle biopsy procedures, including fine-needle aspiration (FNA) and core needle biopsy. FNA uses a thin needle and gentle suction to remove fluid and cells from the area, while core needle biopsy uses a larger needle to remove a small piece of tissue. The type of needle biopsy used depends on the location and size of the abnormal area, as well as the reason for the procedure.

Neoplasm grading is a system used by pathologists to classify the degree of abnormality in cells that make up a tumor (neoplasm). It provides an assessment of how quickly the tumor is likely to grow and spread. The grade helps doctors predict the prognosis and determine the best treatment options.

Neoplasm grading typically involves evaluating certain cellular features under a microscope, such as:

1. Differentiation or degree of maturity: This refers to how closely the tumor cells resemble their normal counterparts in terms of size, shape, and organization. Well-differentiated tumors have cells that look more like normal cells and are usually slower growing. Poorly differentiated tumors have cells that appear very abnormal and tend to grow and spread more aggressively.

2. Mitotic count: This is the number of times the tumor cells divide (mitosis) within a given area. A higher mitotic count indicates a faster-growing tumor.

3. Necrosis: This refers to areas of dead tissue within the tumor. A significant amount of necrosis may suggest a more aggressive tumor.

Based on these and other factors, pathologists assign a grade to the tumor using a standardized system, such as the Bloom-Richardson or Scarff-Bloom-Richardson grading systems for breast cancer or the Fuhrman grading system for kidney cancer. The grade usually consists of a number or a range (e.g., G1, G2, G3, or G4) or a combination of grades (e.g., low grade, intermediate grade, and high grade).

In general, higher-grade tumors have a worse prognosis than lower-grade tumors because they are more likely to grow quickly, invade surrounding tissues, and metastasize (spread) to other parts of the body. However, neoplasm grading is just one aspect of cancer diagnosis and treatment planning. Other factors, such as the stage of the disease, location of the tumor, patient's overall health, and specific molecular markers, are also considered when making treatment decisions.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.

Hematologic neoplasms can be broadly classified into three categories:

1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.

Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Epithelial cells are types of cells that cover the outer surfaces of the body, line the inner surfaces of organs and glands, and form the lining of blood vessels and body cavities. They provide a protective barrier against the external environment, regulate the movement of materials between the internal and external environments, and are involved in the sense of touch, temperature, and pain. Epithelial cells can be squamous (flat and thin), cuboidal (square-shaped and of equal height), or columnar (tall and narrow) in shape and are classified based on their location and function.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

"Prostatism" is not a formal medical term, but it is often used informally to refer to lower urinary tract symptoms (LUTS) that are related to bladder outflow obstruction due to benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland in older men.

The symptoms of prostatism may include:

* Frequency: The need to urinate more often than usual, especially at night.
* Urgency: A strong, sudden need to urinate immediately.
* Nocturia: Waking up frequently during the night to urinate.
* Hesitancy: Difficulty starting the flow of urine.
* Straining: Having to strain or push to start urinating.
* Weak stream: A weak or slow urinary stream.
* Dribbling: Dribbling or leaking after urination is finished.
* Incomplete emptying: Feeling that the bladder is not fully emptied after urination.

It's important to note that these symptoms can also be caused by other conditions, such as urinary tract infections, prostate cancer, or neurological disorders, so a proper medical evaluation is necessary to determine the underlying cause and appropriate treatment.

Urethral obstruction is a medical condition that refers to a blockage in the urethra, which is the tube that carries urine from the bladder out of the body. This blockage can be partial or complete and can be caused by various factors such as scar tissue, stones, tumors, or enlarged prostate gland in men. Symptoms may include difficulty in urinating, painful urination, frequent urination, and urinary retention. If left untreated, urethral obstruction can lead to serious complications such as kidney damage or infection.

Intestinal neoplasms refer to abnormal growths in the tissues of the intestines, which can be benign or malignant. These growths are called neoplasms and they result from uncontrolled cell division. In the case of intestinal neoplasms, these growths occur in the small intestine, large intestine (colon), rectum, or appendix.

Benign intestinal neoplasms are not cancerous and often do not invade surrounding tissues or spread to other parts of the body. However, they can still cause problems if they grow large enough to obstruct the intestines or cause bleeding. Common types of benign intestinal neoplasms include polyps, leiomyomas, and lipomas.

Malignant intestinal neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to other parts of the body. The most common type of malignant intestinal neoplasm is adenocarcinoma, which arises from the glandular cells lining the inside of the intestines. Other types of malignant intestinal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Symptoms of intestinal neoplasms can vary depending on their size, location, and type. Common symptoms include abdominal pain, bloating, changes in bowel habits, rectal bleeding, weight loss, and fatigue. If you experience any of these symptoms, it is important to seek medical attention promptly.

Cyproterone is an anti-androgen medication that works by blocking the action of androgens (male hormones such as testosterone) in the body. It is used to treat conditions such as prostate cancer, hirsutism (excessive hair growth), and severe acne that have not responded to other treatments. Cyproterone is also used in conjunction with estrogen therapy to help reduce sexual desire in individuals with paraphilic disorders or gender identity disorder.

The medication comes in the form of tablets and is usually taken once or twice a day, depending on the condition being treated. Common side effects of cyproterone include breast tenderness, decreased sex drive, and irregular menstrual periods. More serious side effects may include liver damage, blood clots, and an increased risk of certain types of cancer.

It is important to follow the instructions of a healthcare provider when taking cyproterone, as the medication can interact with other medications and have potentially serious side effects. Regular monitoring by a healthcare provider is also necessary to ensure that the medication is working effectively and to monitor for any potential side effects.

Neoplasms, adnexal and skin appendage refer to abnormal growths or tumors that develop in the sweat glands, hair follicles, or other structures associated with the skin. These growths can be benign (non-cancerous) or malignant (cancerous), and they can occur anywhere on the body.

Adnexal neoplasms are tumors that arise from the sweat glands or hair follicles, including the sebaceous glands, eccrine glands, and apocrine glands. These tumors can range in size and severity, and they may cause symptoms such as pain, itching, or changes in the appearance of the skin.

Skin appendage neoplasms are similar to adnexal neoplasms, but they specifically refer to tumors that arise from structures such as hair follicles, nails, and sweat glands. Examples of skin appendage neoplasms include pilomatricomas (tumors of the hair follicle), trichilemmomas (tumors of the outer root sheath of the hair follicle), and sebaceous adenomas (tumors of the sebaceous glands).

It is important to note that while many adnexal and skin appendage neoplasms are benign, some can be malignant and may require aggressive treatment. If you notice any unusual growths or changes in your skin, it is important to consult with a healthcare professional for further evaluation and care.

Semen is a complex, whitish fluid that is released from the male reproductive system during ejaculation. It is produced by several glands, including the seminal vesicles, prostate gland, and bulbourethral glands. Semen contains several components, including sperm (the male reproductive cells), as well as various proteins, enzymes, vitamins, and minerals. Its primary function is to transport sperm through the female reproductive tract during sexual intercourse, providing nutrients and aiding in the protection of the sperm as they travel toward the egg for fertilization.

Lower urinary tract symptoms (LUTS) refer to a group of clinical symptoms related to the lower urinary tract, including the bladder and urethra. These symptoms can be categorized into storage, voiding, and post-micturition symptoms. Storage symptoms include frequency, urgency, nocturia, and urinary incontinence. Voiding symptoms consist of hesitancy, slow stream, straining, and intermittent flow. Post-micturition symptoms include a feeling of incomplete bladder emptying and post-void dribbling. LUTS can be caused by various underlying conditions such as benign prostatic hyperplasia (BPH), overactive bladder (OAB), urinary tract infection, neurogenic bladder dysfunction, or bladder cancer. The evaluation and management of LUTS require a comprehensive assessment of the patient's medical history, physical examination, and appropriate diagnostic tests to determine the underlying cause and develop an effective treatment plan.

The urethra is the tube that carries urine from the bladder out of the body. In males, it also serves as the conduit for semen during ejaculation. The male urethra is longer than the female urethra and is divided into sections: the prostatic, membranous, and spongy (or penile) urethra. The female urethra extends from the bladder to the external urethral orifice, which is located just above the vaginal opening.

Vascular neoplasms are a type of tumor that develops from cells that line the blood vessels or lymphatic vessels. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign vascular neoplasms, such as hemangiomas and lymphangiomas, are usually harmless and may not require treatment unless they cause symptoms or complications. Malignant vascular neoplasms, on the other hand, are known as angiosarcomas and can be aggressive, spreading to other parts of the body and potentially causing serious health problems.

Angiosarcomas can develop in any part of the body but are most commonly found in the skin, particularly in areas exposed to radiation or chronic lymph edema. They can also occur in the breast, liver, spleen, and heart. Treatment for vascular neoplasms depends on the type, location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Sweat gland neoplasms are abnormal growths that develop in the sweat glands. These growths can be benign (noncancerous) or malignant (cancerous). Benign sweat gland neoplasms include hidradenomas and syringomas, which are usually slow-growing and cause little to no symptoms. Malignant sweat gland neoplasms, also known as sweat gland carcinomas, are rare but aggressive cancers that can spread to other parts of the body. They may cause symptoms such as a lump or mass under the skin, pain, swelling, and redness. Treatment typically involves surgical removal of the growth.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Adrenergic alpha-antagonists, also known as alpha-blockers, are a class of medications that block the effects of adrenaline and noradrenaline at alpha-adrenergic receptors. These receptors are found in various tissues throughout the body, including the smooth muscle of blood vessels, the heart, the genitourinary system, and the eyes.

When alpha-blockers bind to these receptors, they prevent the activation of the sympathetic nervous system, which is responsible for the "fight or flight" response. This results in a relaxation of the smooth muscle, leading to vasodilation (widening of blood vessels), decreased blood pressure, and increased blood flow.

Alpha-blockers are used to treat various medical conditions, such as hypertension (high blood pressure), benign prostatic hyperplasia (enlarged prostate), pheochromocytoma (a rare tumor of the adrenal gland), and certain types of glaucoma.

Examples of alpha-blockers include doxazosin, prazosin, terazosin, and tamsulosin. Side effects of alpha-blockers may include dizziness, lightheadedness, headache, weakness, and orthostatic hypotension (a sudden drop in blood pressure upon standing).

Stromal cells, also known as stromal/stroma cells, are a type of cell found in various tissues and organs throughout the body. They are often referred to as the "connective tissue" or "supporting framework" of an organ because they play a crucial role in maintaining the structure and function of the tissue. Stromal cells include fibroblasts, adipocytes (fat cells), and various types of progenitor/stem cells. They produce and maintain the extracellular matrix, which is the non-cellular component of tissues that provides structural support and biochemical cues for other cells. Stromal cells also interact with immune cells and participate in the regulation of the immune response. In some contexts, "stromal cells" can also refer to cells found in the microenvironment of tumors, which can influence cancer growth and progression.

Palatal neoplasms refer to abnormal growths or tumors that occur on the palate, which is the roof of the mouth. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slower growing and less likely to spread, while malignant neoplasms are more aggressive and can invade nearby tissues and organs.

Palatal neoplasms can have various causes, including genetic factors, environmental exposures, and viral infections. They may present with symptoms such as mouth pain, difficulty swallowing, swelling or lumps in the mouth, bleeding, or numbness in the mouth or face.

The diagnosis of palatal neoplasms typically involves a thorough clinical examination, imaging studies, and sometimes biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or spread of the neoplasm.

Androgen antagonists are a class of drugs that block the action of androgens, which are hormones that contribute to male sexual development and characteristics. They work by binding to androgen receptors in cells, preventing the natural androgens from attaching and exerting their effects. This can be useful in treating conditions that are caused or worsened by androgens, such as prostate cancer, hirsutism (excessive hair growth in women), and acne. Examples of androgen antagonists include flutamide, bicalutamide, and spironolactone.

Cell division is the process by which a single eukaryotic cell (a cell with a true nucleus) divides into two identical daughter cells. This complex process involves several stages, including replication of DNA, separation of chromosomes, and division of the cytoplasm. There are two main types of cell division: mitosis and meiosis.

Mitosis is the type of cell division that results in two genetically identical daughter cells. It is a fundamental process for growth, development, and tissue repair in multicellular organisms. The stages of mitosis include prophase, prometaphase, metaphase, anaphase, and telophase, followed by cytokinesis, which divides the cytoplasm.

Meiosis, on the other hand, is a type of cell division that occurs in the gonads (ovaries and testes) during the production of gametes (sex cells). Meiosis results in four genetically unique daughter cells, each with half the number of chromosomes as the parent cell. This process is essential for sexual reproduction and genetic diversity. The stages of meiosis include meiosis I and meiosis II, which are further divided into prophase, prometaphase, metaphase, anaphase, and telophase.

In summary, cell division is the process by which a single cell divides into two daughter cells, either through mitosis or meiosis. This process is critical for growth, development, tissue repair, and sexual reproduction in multicellular organisms.

Colonic neoplasms refer to abnormal growths in the large intestine, also known as the colon. These growths can be benign (non-cancerous) or malignant (cancerous). The two most common types of colonic neoplasms are adenomas and carcinomas.

Adenomas are benign tumors that can develop into cancer over time if left untreated. They are often found during routine colonoscopies and can be removed during the procedure.

Carcinomas, on the other hand, are malignant tumors that invade surrounding tissues and can spread to other parts of the body. Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and colonic neoplasms are a significant risk factor for developing this type of cancer.

Regular screenings for colonic neoplasms are recommended for individuals over the age of 50 or those with a family history of colorectal cancer or other risk factors. Early detection and removal of colonic neoplasms can significantly reduce the risk of developing colorectal cancer.

A biopsy is a medical procedure in which a small sample of tissue is taken from the body to be examined under a microscope for the presence of disease. This can help doctors diagnose and monitor various medical conditions, such as cancer, infections, or autoimmune disorders. The type of biopsy performed will depend on the location and nature of the suspected condition. Some common types of biopsies include:

1. Incisional biopsy: In this procedure, a surgeon removes a piece of tissue from an abnormal area using a scalpel or other surgical instrument. This type of biopsy is often used when the lesion is too large to be removed entirely during the initial biopsy.

2. Excisional biopsy: An excisional biopsy involves removing the entire abnormal area, along with a margin of healthy tissue surrounding it. This technique is typically employed for smaller lesions or when cancer is suspected.

3. Needle biopsy: A needle biopsy uses a thin, hollow needle to extract cells or fluid from the body. There are two main types of needle biopsies: fine-needle aspiration (FNA) and core needle biopsy. FNA extracts loose cells, while a core needle biopsy removes a small piece of tissue.

4. Punch biopsy: In a punch biopsy, a round, sharp tool is used to remove a small cylindrical sample of skin tissue. This type of biopsy is often used for evaluating rashes or other skin abnormalities.

5. Shave biopsy: During a shave biopsy, a thin slice of tissue is removed from the surface of the skin using a sharp razor-like instrument. This technique is typically used for superficial lesions or growths on the skin.

After the biopsy sample has been collected, it is sent to a laboratory where a pathologist will examine the tissue under a microscope and provide a diagnosis based on their findings. The results of the biopsy can help guide further treatment decisions and determine the best course of action for managing the patient's condition.

Urodynamics is a medical test that measures the function and performance of the lower urinary tract, which includes the bladder, urethra, and sphincters. It involves the use of specialized equipment to record measurements such as bladder pressure, urine flow rate, and residual urine volume. The test can help diagnose various urinary problems, including incontinence, urinary retention, and overactive bladder.

During the test, a small catheter is inserted into the bladder through the urethra to measure bladder pressure while filling it with sterile water or saline solution. Another catheter may be placed in the rectum to record abdominal pressure. The patient is then asked to urinate, and the flow rate and any leaks are recorded.

Urodynamics can help identify the underlying cause of urinary symptoms and guide treatment decisions. It is often recommended for patients with complex or persistent urinary problems that have not responded to initial treatments.

Keratins are a type of fibrous structural proteins that constitute the main component of the integumentary system, which includes the hair, nails, and skin of vertebrates. They are also found in other tissues such as horns, hooves, feathers, and reptilian scales. Keratins are insoluble proteins that provide strength, rigidity, and protection to these structures.

Keratins are classified into two types: soft keratins (Type I) and hard keratins (Type II). Soft keratins are found in the skin and simple epithelial tissues, while hard keratins are present in structures like hair, nails, horns, and hooves.

Keratin proteins have a complex structure consisting of several domains, including an alpha-helical domain, beta-pleated sheet domain, and a non-repetitive domain. These domains provide keratin with its unique properties, such as resistance to heat, chemicals, and mechanical stress.

In summary, keratins are fibrous structural proteins that play a crucial role in providing strength, rigidity, and protection to various tissues in the body.

Mandibular neoplasms refer to abnormal growths or tumors that develop in the mandible, which is the lower jawbone. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and rarely spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and may metastasize (spread) to distant sites.

Mandibular neoplasms can have various causes, including genetic mutations, exposure to certain chemicals or radiation, and infection with certain viruses. The symptoms of mandibular neoplasms may include swelling or pain in the jaw, difficulty chewing or speaking, numbness in the lower lip or chin, loose teeth, and/or a lump or mass in the mouth or neck.

The diagnosis of mandibular neoplasms typically involves a thorough clinical examination, imaging studies such as X-rays, CT scans, or MRI scans, and sometimes a biopsy to confirm the type and extent of the tumor. Treatment options depend on the type, stage, and location of the neoplasm, and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or metastasis.

Cystadenocarcinoma is a type of tumor that arises from the epithelial lining of a cyst, and it has the potential to invade surrounding tissues and spread (metastasize) to other parts of the body. It typically affects glandular organs such as the ovaries, pancreas, and salivary glands.

Cystadenocarcinomas can be classified into two types: serous and mucinous. Serous cystadenocarcinomas produce a watery fluid, while mucinous cystadenocarcinomas produce a thick, mucus-like fluid. Both types of tumors can be benign or malignant, but malignant cystadenocarcinomas are more aggressive and have a higher risk of metastasis.

Symptoms of cystadenocarcinoma depend on the location and size of the tumor. In some cases, there may be no symptoms until the tumor has grown large enough to cause pain or other problems. Treatment typically involves surgical removal of the tumor, along with any affected surrounding tissue. Chemotherapy and radiation therapy may also be used in some cases to help prevent recurrence or spread of the cancer.

Tartrates are salts or esters of tartaric acid, a naturally occurring organic acid found in many fruits, particularly grapes. In a medical context, potassium bitartrate (also known as cream of tartar) is sometimes used as a mild laxative or to treat acidosis by helping to restore the body's normal pH balance. Additionally, sodium tartrate has been historically used as an antidote for lead poisoning. However, these uses are not common in modern medicine.

Bile duct neoplasms, also known as cholangiocarcinomas, refer to a group of malignancies that arise from the bile ducts. These are the tubes that carry bile from the liver to the gallbladder and small intestine. Bile duct neoplasms can be further classified based on their location as intrahepatic (within the liver), perihilar (at the junction of the left and right hepatic ducts), or distal (in the common bile duct).

These tumors are relatively rare, but their incidence has been increasing in recent years. They can cause a variety of symptoms, including jaundice, abdominal pain, weight loss, and fever. The diagnosis of bile duct neoplasms typically involves imaging studies such as CT or MRI scans, as well as blood tests to assess liver function. In some cases, a biopsy may be necessary to confirm the diagnosis.

Treatment options for bile duct neoplasms depend on several factors, including the location and stage of the tumor, as well as the patient's overall health. Surgical resection is the preferred treatment for early-stage tumors, while chemotherapy and radiation therapy may be used in more advanced cases. For patients who are not candidates for surgery, palliative treatments such as stenting or bypass procedures may be recommended to relieve symptoms and improve quality of life.

Thymus neoplasms are abnormal growths in the thymus gland that result from uncontrolled cell division. The term "neoplasm" refers to any new and abnormal growth of tissue, also known as a tumor. Thymus neoplasms can be benign or malignant (cancerous).

Malignant thymus neoplasms are called thymomas or thymic carcinomas. Thymomas are the most common type and tend to grow slowly, invading nearby tissues and organs. They can also spread (metastasize) to other parts of the body. Thymic carcinomas are rarer and more aggressive, growing and spreading more quickly than thymomas.

Symptoms of thymus neoplasms may include coughing, chest pain, difficulty breathing, or swelling in the neck or upper chest. Treatment options for thymus neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Epithelium is the tissue that covers the outer surface of the body, lines the internal cavities and organs, and forms various glands. It is composed of one or more layers of tightly packed cells that have a uniform shape and size, and rest on a basement membrane. Epithelial tissues are avascular, meaning they do not contain blood vessels, and are supplied with nutrients by diffusion from the underlying connective tissue.

Epithelial cells perform a variety of functions, including protection, secretion, absorption, excretion, and sensation. They can be classified based on their shape and the number of cell layers they contain. The main types of epithelium are:

1. Squamous epithelium: composed of flat, scalelike cells that fit together like tiles on a roof. It forms the lining of blood vessels, air sacs in the lungs, and the outermost layer of the skin.
2. Cuboidal epithelium: composed of cube-shaped cells with equal height and width. It is found in glands, tubules, and ducts.
3. Columnar epithelium: composed of tall, rectangular cells that are taller than they are wide. It lines the respiratory, digestive, and reproductive tracts.
4. Pseudostratified epithelium: appears stratified or layered but is actually made up of a single layer of cells that vary in height. The nuclei of these cells appear at different levels, giving the tissue a stratified appearance. It lines the respiratory and reproductive tracts.
5. Transitional epithelium: composed of several layers of cells that can stretch and change shape to accommodate changes in volume. It is found in the urinary bladder and ureters.

Epithelial tissue provides a barrier between the internal and external environments, protecting the body from physical, chemical, and biological damage. It also plays a crucial role in maintaining homeostasis by regulating the exchange of substances between the body and its environment.

Splenic neoplasms refer to abnormal growths or tumors in the spleen, which can be benign (non-cancerous) or malignant (cancerous). These growths can arise from various cell types present within the spleen, including hematopoietic cells (red and white blood cells, platelets), stromal cells (supporting tissue), or lymphoid cells (part of the immune system).

There are several types of splenic neoplasms:

1. Hematologic malignancies: These are cancers that affect the blood and bone marrow, such as leukemias, lymphomas, and multiple myeloma. They often involve the spleen, causing enlargement (splenomegaly) and neoplastic infiltration of splenic tissue.
2. Primary splenic tumors: These are rare and include benign lesions like hemangiomas, lymphangiomas, and hamartomas, as well as malignant tumors such as angiosarcoma, littoral cell angiosarcoma, and primary splenic lymphoma.
3. Metastatic splenic tumors: These occur when cancer cells from other primary sites spread (metastasize) to the spleen. Common sources of metastasis include lung, breast, colon, and ovarian cancers, as well as melanomas and sarcomas.

Symptoms of splenic neoplasms may vary depending on the type and extent of the disease but often include abdominal pain or discomfort, fatigue, weight loss, and anemia. Diagnosis typically involves imaging studies (such as ultrasound, CT, or MRI scans) and sometimes requires a biopsy for confirmation. Treatment options depend on the type of neoplasm and may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Diethylstilbestrol (DES) is a synthetic form of the hormone estrogen that was prescribed to pregnant women from the 1940s until the early 1970s to prevent miscarriage, premature labor, and other complications of pregnancy. However, it was later discovered that DES could cause serious health problems in both the mothers who took it and their offspring.

DES is a non-selective estrogen agonist, meaning that it binds to and activates both estrogen receptors (ERα and ERβ) in the body. It has a higher binding affinity for ERα than for ERβ, which can lead to disruptions in normal hormonal signaling pathways.

In addition to its use as a pregnancy aid, DES has also been used in the treatment of prostate cancer, breast cancer, and other conditions associated with hormonal imbalances. However, due to its potential health risks, including an increased risk of certain cancers, DES is no longer widely used in clinical practice.

Some of the known health effects of DES exposure include:

* In women who were exposed to DES in utero (i.e., their mothers took DES during pregnancy):
+ A rare form of vaginal or cervical cancer called clear cell adenocarcinoma
+ Abnormalities of the reproductive system, such as structural changes in the cervix and vagina, and an increased risk of infertility, ectopic pregnancy, and preterm delivery
+ An increased risk of breast cancer later in life
* In men who were exposed to DES in utero:
+ Undescended testicles
+ Abnormalities of the penis and scrotum
+ A higher risk of testicular cancer
* In both men and women who were exposed to DES in utero or who took DES themselves:
+ An increased risk of certain types of breast cancer
+ A possible increased risk of cardiovascular disease, including high blood pressure and stroke.

It is important for individuals who have been exposed to DES to inform their healthcare providers of this fact, as it may have implications for their medical care and monitoring.

Heart neoplasms are abnormal growths or tumors that develop within the heart tissue. They can be benign (noncancerous) or malignant (cancerous). Benign tumors, such as myxomas and rhabdomyomas, are typically slower growing and less likely to spread, but they can still cause serious complications if they obstruct blood flow or damage heart valves. Malignant tumors, such as angiosarcomas and rhabdomyosarcomas, are fast-growing and have a higher risk of spreading to other parts of the body. Symptoms of heart neoplasms can include shortness of breath, chest pain, fatigue, and irregular heart rhythms. Treatment options depend on the type, size, and location of the tumor, and may include surgery, radiation therapy, or chemotherapy.

A serous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the serous glands, which are glands that produce a watery, lubricating fluid. This type of tumor typically develops in the ovary or the pancreas.

Serous cystadenomas of the ovary are usually filled with a clear, watery fluid and have multiple loculations (compartments). They can vary in size from a few millimeters to several centimeters in diameter. Although these tumors are benign, they can cause symptoms if they become large enough to press on surrounding organs or if they rupture and release their contents into the abdominal cavity.

Serous cystadenomas of the pancreas are less common than ovarian serous cystadenomas. They typically occur in the tail of the pancreas and can range in size from a few millimeters to several centimeters in diameter. These tumors are usually asymptomatic, but they can cause symptoms such as abdominal pain or discomfort if they become large enough to press on surrounding organs.

It is important to note that while serous cystadenomas are generally benign, there is a small risk that they may undergo malignant transformation and develop into a type of cancer known as a serous cystadenocarcinoma. For this reason, it is important for patients with these tumors to be followed closely by a healthcare provider and to have regular imaging studies and/or surgical excision to monitor for any changes in the tumor.

Maxillary neoplasms refer to abnormal growths or tumors in the maxilla, which is the upper jaw bone. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and spread to distant sites.

Maxillary neoplasms can cause various symptoms such as swelling, pain, numbness, loose teeth, or difficulty in chewing or swallowing. They may also cause nasal congestion, nosebleeds, or visual changes if they affect the eye or orbit. The diagnosis of maxillary neoplasms usually involves a combination of clinical examination, imaging studies such as CT or MRI scans, and biopsy to determine the type and extent of the tumor.

Treatment options for maxillary neoplasms depend on several factors, including the type, size, location, and stage of the tumor, as well as the patient's overall health and preferences. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis and ensure optimal outcomes.

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

Anal gland neoplasms, also known as anal sac tumors, are abnormal growths that develop from the cells lining the anal glands. These glands are located on either side of the anus in dogs and some other animals, and they produce a scent used for marking territory.

Anal gland neoplasms can be benign or malignant (cancerous). Malignant tumors are more common and tend to grow quickly, invading surrounding tissues and spreading to other parts of the body (metastasis). Common symptoms of anal gland neoplasms include straining to defecate, bleeding from the rectum, and a firm mass that can be felt near the anus.

Treatment for anal gland neoplasms typically involves surgical removal of the tumor. In some cases, radiation therapy or chemotherapy may also be recommended. The prognosis for animals with anal gland neoplasms depends on several factors, including the size and location of the tumor, whether it has spread to other parts of the body, and the overall health of the animal.

Colorectal neoplasms refer to abnormal growths in the colon or rectum, which can be benign or malignant. These growths can arise from the inner lining (mucosa) of the colon or rectum and can take various forms such as polyps, adenomas, or carcinomas.

Benign neoplasms, such as hyperplastic polyps and inflammatory polyps, are not cancerous but may need to be removed to prevent the development of malignant tumors. Adenomas, on the other hand, are precancerous lesions that can develop into colorectal cancer if left untreated.

Colorectal cancer is a malignant neoplasm that arises from the uncontrolled growth and division of cells in the colon or rectum. It is one of the most common types of cancer worldwide and can spread to other parts of the body through the bloodstream or lymphatic system.

Regular screening for colorectal neoplasms is recommended for individuals over the age of 50, as early detection and removal of precancerous lesions can significantly reduce the risk of developing colorectal cancer.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Urology is a surgical specialty that deals with the diagnosis and treatment of diseases and conditions related to the male and female urinary tract system and the male reproductive organs. This includes the kidneys, ureters, bladder, prostate gland, and testicles. Urologists are medical doctors who have completed specialized training in this field, and they may perform various surgical procedures such as cystoscopy, lithotripsy, and radical prostatectomy to treat conditions like kidney stones, urinary tract infections, bladder cancer, enlarged prostate, and infertility.

Neoplasms, germ cell and embryonal are types of tumors that originate from the abnormal growth of cells. Here's a brief medical definition for each:

1. Neoplasms: Neoplasms refer to abnormal tissue growths or masses, which can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled cell division and may invade surrounding tissues or spread to other parts of the body through a process called metastasis.
2. Germ Cell Tumors: These are rare tumors that develop from the germ cells, which give rise to sperm and eggs in the reproductive organs (ovaries and testes). They can be benign or malignant and may occur in both children and adults. Germ cell tumors can also arise outside of the reproductive organs, a condition known as extragonadal germ cell tumors.
3. Embryonal Tumors: These are a type of malignant neoplasm that primarily affects infants and young children. They develop from embryonic cells, which are immature cells present during fetal development. Embryonal tumors can occur in various organs, including the brain (medulloblastomas), nervous system (primitive neuroectodermal tumors or PNETs), and other areas like the kidneys and liver.

It is essential to note that these conditions require professional medical evaluation and treatment by healthcare professionals with expertise in oncology and related fields.

Bone marrow neoplasms are a type of cancer that originates in the bone marrow, which is the spongy tissue inside bones where blood cells are produced. These neoplasms can be divided into two main categories: hematologic (or liquid) malignancies and solid tumors.

Hematologic malignancies include leukemias, lymphomas, and multiple myeloma. Leukemias are cancers of the white blood cells, which normally fight infections. In leukemia, the bone marrow produces abnormal white blood cells that do not function properly, leading to an increased risk of infection, anemia, and bleeding.

Lymphomas are cancers of the lymphatic system, which helps to fight infections and remove waste from the body. Lymphoma can affect the lymph nodes, spleen, thymus gland, and bone marrow. There are two main types of lymphoma: Hodgkin's lymphoma and non-Hodgkin's lymphoma.

Multiple myeloma is a cancer of the plasma cells, which are a type of white blood cell that produces antibodies to help fight infections. In multiple myeloma, abnormal plasma cells accumulate in the bone marrow and produce large amounts of abnormal antibodies, leading to bone damage, anemia, and an increased risk of infection.

Solid tumors of the bone marrow are rare and include conditions such as chordomas, Ewing sarcomas, and osteosarcomas. These cancers originate in the bones themselves or in other tissues that support the bones, but they can also spread to the bone marrow.

Treatment for bone marrow neoplasms depends on the type and stage of cancer, as well as the patient's overall health. Treatment options may include chemotherapy, radiation therapy, stem cell transplantation, targeted therapy, or a combination of these approaches.

A precancerous condition, also known as a premalignant condition, is a state of abnormal cellular growth and development that has a higher-than-normal potential to progress into cancer. These conditions are characterized by the presence of certain anomalies in the cells, such as dysplasia (abnormal changes in cell shape or size), which can indicate an increased risk for malignant transformation.

It is important to note that not all precancerous conditions will eventually develop into cancer, and some may even regress on their own. However, individuals with precancerous conditions are often at a higher risk of developing cancer compared to the general population. Regular monitoring and appropriate medical interventions, if necessary, can help manage this risk and potentially prevent or detect cancer at an early stage when it is more treatable.

Examples of precancerous conditions include:

1. Dysplasia in the cervix (cervical intraepithelial neoplasia or CIN)
2. Atypical ductal hyperplasia or lobular hyperplasia in the breast
3. Actinic keratosis on the skin
4. Leukoplakia in the mouth
5. Barrett's esophagus in the digestive tract

Regular medical check-ups, screenings, and lifestyle modifications are crucial for individuals with precancerous conditions to monitor their health and reduce the risk of cancer development.

Urologic diseases refer to a variety of conditions that affect the urinary tract, which includes the kidneys, ureters, bladder, and urethra in both males and females, as well as the male reproductive system. These diseases can range from relatively common conditions such as urinary tract infections (UTIs) and benign prostatic hyperplasia (BPH), to more complex diseases like kidney stones, bladder cancer, and prostate cancer.

Some of the common urologic diseases include:

1. Urinary Tract Infections (UTIs): These are infections that occur in any part of the urinary system, including the kidneys, ureters, bladder, and urethra. UTIs are more common in women than men.
2. Kidney Stones: These are small, hard mineral deposits that form inside the kidneys and can cause pain, nausea, and blood in the urine when passed.
3. Benign Prostatic Hyperplasia (BPH): This is a non-cancerous enlargement of the prostate gland that can cause difficulty urinating, frequent urination, and a weak urine stream.
4. Bladder Cancer: This is a type of cancer that begins in the bladder, usually in the lining of the bladder.
5. Prostate Cancer: This is a type of cancer that occurs in the prostate gland, which is a small walnut-shaped gland in men that produces seminal fluid.
6. Erectile Dysfunction (ED): This is a condition where a man has trouble achieving or maintaining an erection.
7. Overactive Bladder (OAB): This is a condition characterized by the sudden and strong need to urinate frequently, as well as involuntary loss of urine (incontinence).

Urologic diseases can affect people of all ages and genders, although some conditions are more common in certain age groups or among men or women. Treatment for urologic diseases varies depending on the specific condition and its severity, but may include medication, surgery, or lifestyle changes.

Organ size refers to the volume or physical measurement of an organ in the body of an individual. It can be described in terms of length, width, and height or by using specialized techniques such as imaging studies (like CT scans or MRIs) to determine the volume. The size of an organ can vary depending on factors such as age, sex, body size, and overall health status. Changes in organ size may indicate various medical conditions, including growths, inflammation, or atrophy.

Neoplasms in adipose tissue refer to abnormal and excessive growths of cells that form tumors within the fatty connective tissue. These neoplasms can be benign or malignant (cancerous). Benign neoplasms, such as lipomas, are slow-growing and typically do not spread to other parts of the body. Malignant neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to distant sites in the body (metastasis). An example of a malignant neoplasm in adipose tissue is liposarcoma. It's important to note that while some neoplasms may not cause any symptoms, others can cause pain, swelling or other uncomfortable sensations, and therefore should be evaluated by a medical professional for proper diagnosis and treatment.

Meningeal neoplasms, also known as malignant meningitis or leptomeningeal carcinomatosis, refer to cancerous tumors that originate in the meninges, which are the membranes covering the brain and spinal cord. These tumors can arise primarily from the meningeal cells themselves, although they more commonly result from the spread (metastasis) of cancer cells from other parts of the body, such as breast, lung, or melanoma.

Meningeal neoplasms can cause a variety of symptoms, including headaches, nausea and vomiting, mental status changes, seizures, and focal neurological deficits. Diagnosis typically involves imaging studies (such as MRI) and analysis of cerebrospinal fluid obtained through a spinal tap. Treatment options may include radiation therapy, chemotherapy, or surgery, depending on the type and extent of the tumor. The prognosis for patients with meningeal neoplasms is generally poor, with a median survival time of several months to a year.

Duodenal neoplasms refer to abnormal growths in the duodenum, which is the first part of the small intestine that receives digestive secretions from the pancreas and bile duct. These growths can be benign or malignant (cancerous).

Benign neoplasms include adenomas, leiomyomas, lipomas, and hamartomas. They are usually slow-growing and do not spread to other parts of the body. However, they may cause symptoms such as abdominal pain, bleeding, or obstruction of the intestine.

Malignant neoplasms include adenocarcinomas, neuroendocrine tumors (carcinoids), lymphomas, and sarcomas. They are more aggressive and can invade surrounding tissues and spread to other parts of the body. Symptoms may include abdominal pain, weight loss, jaundice, anemia, or bowel obstruction.

The diagnosis of duodenal neoplasms is usually made through imaging tests such as CT scans, MRI, or endoscopy with biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these modalities.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Metribolone is a synthetic anabolic-androgenic steroid (AAS) drug, which is not widely used in clinical medicine. Its chemical structure and pharmacological properties are similar to the natural male hormone testosterone. It has been used in research settings to study its effects on muscle growth, bone density, and sexual development. However, due to its potential for abuse and serious side effects, it is not approved for use in many countries.

It's important to note that the possession, distribution, and use of anabolic steroids without a valid prescription is illegal and can be dangerous to one's health. It can cause a range of adverse effects such as liver damage, cardiovascular disease, hormonal imbalances, and psychological issues among others.

Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Der Urologe (in German). 10 (3): 117- ... Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, Slayton R (1981). "Treatment of stage D prostatic carcinoma with ... Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 277-. ISBN 978-1-4612-5476-8. Gordon JD ( ... Lebech PE, Nordentoft EL (1967). "A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol ...
Armenian HK, Lilienfeld AM, Diamond EL, Bross IDJ: Epidemiologic Characteristics of Patients with Prostatic Neoplasms, American ... Armenian HK, Lilienfeld AM, Diamond EL, Bross IDJ: Relation Between Benign Prostatic Hyperplasia to Cancer of the Prostate. A ... Armenian HK: The Relationship of Benign Prostatic Hyperplasia to Cancer of the Prostate. An Epidemiological Study. Johns ...
MeSH C12.294.260.500 - penile neoplasms MeSH C12.294.260.750 - prostatic neoplasms MeSH C12.294.260.937 - testicular neoplasms ... genital neoplasms, male MeSH C12.740.800.410.600 - penile neoplasms MeSH C12.740.800.410.650 - prostatic neoplasms MeSH C12.740 ... prostatic hyperplasia MeSH C12.294.565.625 - prostatic neoplasms MeSH C12.294.565.750 - prostatitis MeSH C12.294.644.486 - ... 875 - testicular neoplasms MeSH C12.740.800.820 - urologic neoplasms MeSH C12.740.800.820.125 - bladder neoplasms MeSH C12.740. ...
Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the original on 2011-07- ... The prostatic veins form a well-marked prostatic plexus which lies partly in the fascial sheath of the prostate and partly ... The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic ... The prostatic venous plexus drains into the internal iliac vein which in turn connects with the vertebral venous plexus; this ...
Some neoplasms of the genitourinary system may present with haematospermia. Malignant causes of haematospermia include; ... Various prostate pathologies (including prostatitis, calculi (stones), cysts, benign prostatic hyperplasia, bacterial infection ...
These are typically found incidentally on surgery for benign prostatic hyperplasia (Note: not a precursor lesion for prostatic ... Neoplasms have no glandular differentiation (thus not resembling normal prostate tissue at all). It is composed of sheets ( ... In prostatic adenocarcinoma, the basal (bottom, usually cuboidal type) cell layer is lost, with only the top layer (usually ... This recognizes that prostatic carcinomas have multiple patterns and that prognosis is more accurately determined by adding the ...
... genital neoplasms, male MeSH C04.588.945.440.715 - penile neoplasms MeSH C04.588.945.440.770 - prostatic neoplasms MeSH C04.588 ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ... femoral neoplasms MeSH C04.588.149.721 - skull neoplasms MeSH C04.588.149.721.450 - jaw neoplasms MeSH C04.588.149.721.450.583 ...
Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds ... an accurate monitor of hormone treatment in prostatic cancer". Br J Urol. 45 (6): 668-77. doi:10.1111/j.1464-410x.1973.tb12238. ...
It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia, although it is currently seldom ... Due to its 5-HT2A receptor antagonism, phenoxybenzamine is useful in the treatment of carcinoid tumor, a neoplasm that secretes ... "A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction". British Journal of ...
... has been studied in the treatment of benign prostatic hyperplasia (BPH) in a 24-week trial of 15 patients at a ... Approximately 96% of bicalutamide prescriptions were written for diagnosis codes that clearly indicated neoplasm. About 1,200, ... Kenny B, Ballard S, Blagg J, Fox D (1997). "Pharmacological options in the treatment of benign prostatic hyperplasia". J. Med. ... Newling DW (1990). "The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter ...
Some pathology grading systems apply only to malignant neoplasms (cancer); others apply also to benign neoplasms. The ... "Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974". J. Urol. ... In pathology, grading is a measure of the cell appearance in tumors and other neoplasms. ...
NOS M8000/6 Neoplasm, metastatic Neoplasm, metastatic Tumor, metastatic Tumor, secondary Tumor embolus M8000/9 Neoplasm, ... grade III Prostatic intraepithelial neoplasia, grade III (C61.9) PIN III M8149/0 Canalicular adenoma M8150/0 Islet cell adenoma ... benign M8000/1 Neoplasm, uncertain whether benign or malignant Neoplasm, NOS Tumor, NOS Unclassified tumor, uncertain whether ... M8130/1 Papillary transitional cell neoplasm of low malignant potential (C67._) Papillary urothelial neoplasm of low malignant ...
High-grade prostatic intraepithelial neoplasia is equivalent to CIS of the prostate. Bronchioloalveolar carcinoma (BAC) of the ... While they are a form of neoplasm, there is disagreement over whether CIS should be classified as cancer. This controversy also ...
Even rarer neoplasms include sarcoma, squamous cell carcinoma, yolk sac tumor, neuroendocrine carcinoma, paraganglioma, ... The ejaculatory ducts pass through the prostate gland before opening separately into the verumontanum of the prostatic urethra ... or prostatic urethra. The evolution of seminal vesicles may have been influenced by sexual selection. They occur in many groups ...
"Strontium-89 chloride for pain palliation in prostatic skeletal malignancy". The British Journal of Radiology. 64 (765): 816- ... Radioactive strontium for treating incurable pain in skeletal neoplasms]. Deutsche Medizinische Wochenschrift (in German). 98 ( ...
Usman M, Moore W, Talati R, Watkins K, Bilfinger TV (June 2012). "Irreversible electroporation of lung neoplasm: a case series ... Prostate Cancer and Prostatic Diseases. 17 (4): 343-7. doi:10.1038/pcan.2014.33. PMC 4227889. PMID 25179590. Ting F, Tran M, ... Prostate Cancer and Prostatic Diseases. 19 (1): 46-52. doi:10.1038/pcan.2015.47. PMID 26458959. S2CID 6206548. Blazevski A, ...
Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms). Germ line mutations in DNA repair ... Human neoplasias, including thyroid, prostatic, cervical, colorectal, pancreatic and ovarian carcinoma, show a strong increase ...
In older adults, the most common cause of hydronephrosis is benign prostate hyperplasia (BPH), or intrapelvic neoplasms such as ... Lower urinary tract obstruction (such as that caused by bladder outflow obstruction secondary to prostatic hypertrophy) is ... such as from prostatic hypertrophy in older male adults). In pregnancy, dextrorotation (rotation to the right) of the uterus ...
... familial Prostatic malacoplakia associated with prostatic abscess Prostatitis Protein C deficiency Protein-energy malnutrition ... familial Pancreatic diseases Pancreatic islet cell neoplasm Pancreatic islet cell tumors Pancreatic lipomatosis duodenal ... et varioliformis acuta Pityriasis rubra pilaris Piussan-Lenaerts-Mathieu syndrome Placenta disorder Placenta neoplasm Placental ... retardation-hyperkeratosis Parapsoriasis Parasitophobia Parastremmatic dwarfism Parathyroid cancer Parathyroid neoplasm ...
Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 (Suppl 7): 1929-1936. doi:10.1002/ ... "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli, David G. Johns (eds.). ... 548-. ISBN 978-3-642-96158-8. Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 ( ... A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic ...
... prostatic acid phosphatase - prostatic intraepithelial neoplasia - prostatitis - protease inhibitor - protein kinase C - ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... benign prostatic hyperplasia - benign prostatic hypertrophy - benign tumor - benzaldehyde - benzoylphenylurea - benzydamine - ... Hürthle cell neoplasm - hydrazine sulfate - hydromorphone - hydronephrosis - hydroureter - hydroxychloroquine - hydroxyurea - ...
"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms". Clinical Cancer Research. 9 (17): ... and NY-ESO-1 in cancerous and benign prostatic tissue". The Prostate. 66 (1): 13-8. doi:10.1002/pros.20312. PMID 16114059. ...
Ekman P, Lewenhaupt A (1991). "Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic ... Lipkin M, Deschner E, Troncale F (1970). "Cell differentiation and the development of colonic neoplasms". CA: A Cancer Journal ... Lewenhaupt A, Ekman P, Eneroth P, Nilsson B (1990). "Tumour markers as prognostic aids in prostatic carcinoma". British Journal ... Letocha H, Eklöv S, Gronowitz S, Norlén BJ, Nilsson S (1996). "Deoxythymidine kinase in the staging of prostatic adenocarcinoma ...
Hinkel A, Berges RR, Pannek J, Schulze H, Senge T (1996). "Cyproterone acetate in the treatment of advanced prostatic cancer: ... ISBN 978-0-323-32195-2. Meningeal Neoplasms-Advances in Research and Treatment: 2012 Edition: ScholarlyBrief. ScholarlyEditions ... Roila F, Crinò L, Carloni G, Natalini G (September 1993). "Cyproterone acetate: hepatotoxicity and prostatic cancer treatment ... Prostate Cancer Prostatic Dis. 8 (2): 140-51. doi:10.1038/sj.pcan.4500800. PMID 15852051. Green HJ, Pakenham KI, Headley BC, ...
Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 266-. ISBN 978-1-4612-5476-8. Archived ... Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds ... Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R (July 1965). "Treatment of benign prostatic hypertrophy with ... LH P < 0.05, LH/FSH P < 0.01). Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 266-. ISBN ...
It has been theorized that androstanolone may have less risk of benign prostatic hyperplasia and prostate cancer than ... Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DJ (eds ... and in Australia for the treatment of benign prostatic hyperplasia (BPH). It reached phase II clinical trials for hypogonadism ...
Benign prostatic hyperplasia, or BPH, is a noncancerous condition that commonly affects men over the age of 50. The prostate ... such as osteoporosis or underlying neoplasm. Analogous to vertebroplasty, the purpose of sacroplasty is to provide ... "Prostate Enlargement (Benign Prostatic Hyperplasia) , NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases ...
... deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ... Prostate Cancer Prostatic Dis. 17 (3): 213-9. doi:10.1038/pcan.2014.16. PMID 24819234. S2CID 27184844. Qin X, Cui Y, Shen L, ...
Genital Diseases, Male - Prostatic Neoplasms PubMed MeSh Term *Overview. Overview. subject area of * A basal-enriched microRNA ... Diffuse Reflectance Spectroscopy Can Differentiate High Grade and Low Grade Prostatic Carcinoma Conference Proceeding ...
by International Consultation on Benign Prostatic Hyperplasia (2nd : 1993: Paris, France) , Cockett, Abraham T. K , Khoury, ... The 2nd [Second] International Consultation on Benign Prostatic Hyperplasia (BPH, Paris, June 27-30, 1993 : proceedings / ...
Prostatic neoplasm. Additional Information & Resources. Genetic Testing Information. *Genetic Testing Registry: Familial ...
Neoplasm Invasiveness * Patient Selection * Practice Patterns, Physicians* * Prostatic Neoplasms / pathology * Prostatic ...
Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Der Urologe (in German). 10 (3): 117- ... Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, Slayton R (1981). "Treatment of stage D prostatic carcinoma with ... Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 277-. ISBN 978-1-4612-5476-8. Gordon JD ( ... Lebech PE, Nordentoft EL (1967). "A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol ...
Prostatic Neoplasms / genetics* * Retrospective Studies Grants and funding * P50 CA90386-05S2/CA/NCI NIH HHS/United States ...
Conditions: prostate cancer, prostatic neoplasms. *Phase: Not Applicable. *Trial ID: NCT05918263. *Protocol ID: 23-119 ... Conditions: metastatic malignant neoplasm in the bone, prostate adenocarcinoma, stage iii prostate cancer ajcc v8, stage iiia ... Metacure: Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Prostatic Adenocarcinoma. Trial ...
Condition: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic ...
IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose ... IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose ... IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose ...
Uroliths, neoplasms and strictures (especially of urethra). *Herniated urinary bladder. *Prostatic cysts, abscesses, or ...
Prostatic neoplasms/radiotherapy. Resumé en anglais. INTRODUCTION: Patients with low-risk prostate adenocarcinoma may be very ...
Prostatic Neoplasms, Castration-Resistant. *Single Nucleotide Polymorphism. *Tumor Burden. *Drug Resistance. *Quality of Life ...
Prostatic Neoplasms. .map{width:100%;height:300px;margin-bottom:15px;} Name. Location. ...
Prostatic Neoplasms (ortholog); FOUND IN lipid droplet (ortholog); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4,4- ... Prostatic Neoplasms ISO. LDAH (Homo sapiens). 11554173. CTD Direct Evidence: marker/mechanism. CTD. PMID:20676098. ...
Prostatic Neoplasms. Beaver LM, Kuintzle R, Buchanan A, Wiley MW, Glasser ST, Wong CP, Johnson GS, Chang JH, Löhr CV, Williams ...
Adrenal Gland Neoplasms. Prostate. Prostatic Neoplasms. Fiducial Markers. Robotics. Needles. Ablation Techniques. ... Liver Neoplasms. Kidney Neoplasms. Magnetic Resonance Imaging. Magnetic Resonance Imaging, Interventional. Surgery, Computer- ...
Prostatic Neoplasms. Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, Ho E. 2017. The phytochemical ... Neoplasm Proteins. Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, Ho E. 2017. The phytochemical 3 ...
Prostatic Neoplasms. .map{width:100%;height:300px;margin-bottom:15px;} Name. Location. ...
Weve found 16 total result s for "Prostatic Neoplasms". Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection To determine the ...
Ovarian Neoplasms. Prostatic Neoplasms Publication Types: Lecture. Webcast Download. NLM Classification: WP 322 ...
Categories: Prostatic Neoplasms Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted ...
Prostatic Neoplasms (Prostate Cancer) 05/01/2015 - "Cryoablation has been proven as a less invasive, safe, and effective ... Neoplasm Metastasis (Metastasis) 02/01/2013 - "In a single-institution retrospective study of data from December 2003 to ... Neoplasms (Cancer) 11/01/2014 - "Accumulating data have demonstrated that cryoablation is highly effective in local tumor ... 10/01/1997 - "As performed in this series cryosurgery was poorly effective for local control of prostatic carcinoma. ". 05/01/ ...
Prostate Cancer (Prostatic Neoplasm) * Urologic Emergencies Hospital Affiliations. Dr. Cahoon is affiliated (can practice and ...
Prostatic Neoplasms. How long have you been taking it?. Choose one *Less than a week ...
Prostatic Neoplasms. How long have you been taking it?. Choose one *Less than a week ...
Prostatic Neoplasms. *Reconstructive Surgery. *Regenerative Medicine. *Regenerative Medicine, Tissue Engineering, Stem Cells ...
Prostatic involvement by lymphoma and leukemia is rare in surgical pathology practice. In the 2 largest consecutive series, ... Secondary prostatic leukemia/lymphoma is often discovered incidental to a diagnosis of prostatic adenocarcinoma. [11] Symptoms ... Which molecular findings are characteristic of prostatic lymphoma/leukemia?. What is the prognosis of prostatic lymphoma/ ... In a large series of primary prostatic lymphomas, which notably included numerous high-grade secondary prostatic lymphomas in ...
Neoplasms 6% * Pharmaceutical Preparations 5% * Prostatic Neoplasms 5% * Hormones 4% * Logistic Models 4% ...
KEY WORDS: Prostatic neoplasms - Fluoromethylcholine - Choline. inizio pagina. Copyright © 2023 Edizioni Minerva Medica ...
Prostatic Neoplasms. *Reconstructive Surgery. *Regenerative Medicine. *Regenerative Medicine, Tissue Engineering, Stem Cells ...
  • Screening for prostate-specific antigen (PSA) has led to earlier detection of prostate cancer 3 , but elevated serum PSA levels may be present in non-malignant conditions such as benign prostatic hyperlasia (BPH). (nature.com)
  • Although it has not been approved for these uses, MGA has been studied and/or used off-label for a variety of indications including menopausal hormone therapy and the treatment of hot flashes, gynecological/menstrual disorders, endometriosis, endometrial hyperplasia, ovarian cancer, prostate cancer, benign prostatic hyperplasia, male breast cancer, and precocious puberty. (wikipedia.org)
  • Results: Eighty-six patients had a primary diagnosis of benign prostatic hyperplasia (BPH), 35 had urethral strictures,13 had prostate cancer, two had BPH and urethral strictures, and one participant had bladder cancer. (bvsalud.org)
  • that is, precursor lesions to prostatic carcinoma . (medscape.com)
  • HGPIN is characterized by architecturally benign prostatic acini and ducts lined with atypical cells whose morphologic, histochemical, immunohistochemical, and genetic changes are similar to those of prostate cancer. (medscape.com)
  • Male farm workers showed increased risks for benign prostatic hypertrophy. (cdc.gov)
  • Female farm workers showed increased risks for uterovaginal prolapse, acute myocardial infarction, diseases of the skin and subcutaneous tissue, and neoplasms. (cdc.gov)
  • Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. (musc.edu)
  • Secondary prostatic leukemia/lymphoma is often discovered incidental to a diagnosis of prostatic adenocarcinoma. (medscape.com)
  • Taken as a group, primary and secondary prostatic leukemia/lymphoma most commonly presents in the seventh decade. (medscape.com)
  • [ 1 ] Secondary prostatic leukemia/lymphoma may also present with obstructive symptoms. (medscape.com)
  • [ 9 ] One of the largest series contains 62 prostatic lymphomas based on the archives of three major academic medical centers, of which 22 (35%) were primary to the prostate. (medscape.com)
  • [ 10 ] In another series, 8 of 29 (28%) were primary prostatic lymphomas. (medscape.com)
  • Below is the selection of side effect reports (a.k.a. adverse event reports) related to Eligard (Leuprolide) where reactions include prostatic specific antigen increased. (druglib.com)
  • Although it has not been approved for these uses, MGA has been studied and/or used off-label for a variety of indications including menopausal hormone therapy and the treatment of hot flashes, gynecological/menstrual disorders, endometriosis, endometrial hyperplasia, ovarian cancer, prostate cancer, benign prostatic hyperplasia, male breast cancer, and precocious puberty. (wikipedia.org)
  • most of these were presented as a few isolated case reports and without distinction from other spindle cell neoplasms of the prostate. (medscape.com)
  • The prostate has a complex stromal-epithelial interaction that responds to hormonal stimulation that is responsible for prostatic epithelial morphogenesis, differentiation, proliferation, and expression of prostate-specific proteins. (medscape.com)
  • Elevated serum PSA concentrations have been reported in patients with prostate cancer, benign prostatic hypertrophy, or inflammatory conditions of other adjacent genitourinary tissues, but not in apparently healthy men, or men with non-prostatic carcinoma. (cdc.gov)
  • Each of the three anatomically distinct zones of the prostate has its own set of periurethral main prostatic ducts lined by several layers of urothelial-like cells, reminiscent of the urothelium. (bmj.com)
  • The tall columnar cells lining the larger ducts resemble the cells lining the smaller ducts and acini in their staining patterns with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). (bmj.com)
  • Materials and methods: Thirty-nine patients diagnosed with prostate cancer and 34 benign prostatic hyperplasia (BPH) patients who were diagnosed in 2010 met the study criteria. (tubitak.gov.tr)
  • This study was done to identify the rates of incidentally detected prostate cancer in patients undergoing surgical management of Benign Prostatic Hyperplasia (BPH) in our centre. (nepjol.info)
  • PSA is present in normal, benign hyperplastic, and malignant prostatic tissue, in metastatic prostatic carcinoma, and also in prostatic fluid and seminal plasma. (cdc.gov)
  • Indeed, even in benign tissue, transverse sections of prostatic ducts are indistinguishable from acini. (bmj.com)
  • Diagnostic data were in agreement with a benign prostatic obstruction based on benign prostatic enlargement. (hindawi.com)
  • Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. (nih.gov)
  • Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma. (ucdenver.edu)
  • 5. [Cerebral metastasis from prostatic neoplasm simulating meningioma. (nih.gov)
  • 6. Brain metastasis: an unusual complication from prostatic adenocarcinoma. (nih.gov)
  • 10. [Dural metastasis of prostatic adenocarcinoma presenting as acute intracranial subdural hematoma: a case report]. (nih.gov)
  • 12. Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma. (nih.gov)
  • Illustrating this fact, the well-described ductal subtype of prostatic adenocarcinoma is frequently associated with conventional-type acinar adenocarcinoma, and has a tendency to propagate within adjacent intact prostatic ducts. (bmj.com)
  • Lesions with ductal morphology include ductal adenocarcinoma, prostatic intraepithelial neoplasia, as well as the intraductal spread of an adjacent, generally high-grade (Gleason score 8-10) adenocarcinoma. (bmj.com)
  • Although immunotherapy with the Food and Drug Administration‐approved vaccine sipuleucel‐T, which targets prostatic acid phosphatase (PAP), extends survival for 2-4 months, the identification of new immunogenic tumor-associated antigens (TAAs) continues to be an unmet need. (bmj.com)
  • 1 The peri-urethral ducts give off branches, with tributaries adopting the epithelial morphology of prostatic acini as they progress upstream from the urethra (fig 1). (bmj.com)
  • By current convention, all high-grade intra-acinar and intraductal neoplastic lesions of prostatic origin fall under the diagnostic umbrella term: prostatic intraepithelial neoplasm (PIN). (bmj.com)
  • Flutamide versus stilboestrol in the management of advanced prostatic cancer. (nih.gov)
  • In a prospective randomised study the effect of flutamide 750 mg daily was compared with that of stilboestrol 3 mg daily in the treatment of 40 previously untreated patients with advanced prostatic cancer. (nih.gov)
  • Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. (nih.gov)
  • Treatment of advanced prostatic cancer with flutamide. (nih.gov)
  • Flutamide therapy for advanced prostatic cancer: a phase II study. (nih.gov)
  • Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer? (nih.gov)
  • Recently reported research indicates that PSA may serve as an accurate marker for assessing response to treatment in patients with stages B2 to D1 prostatic cancer. (cdc.gov)
  • Serial measurement of PSA concentrations can be an important tool in monitoring patients with prostatic cancer and in determining the potential and actual effectiveness of surgery or other therapies. (cdc.gov)
  • Immunohistochemical studies have shown that PSA is confined to the cytoplasm of prostatic acinar cells and ductal epithelium. (cdc.gov)
  • This article reviews the prostatic lesions with ductal morphology, as well as their mimics, in the hope of guiding anatomical pathologists towards accurate diagnosis and effective reporting of these frequently challenging lesions. (bmj.com)
  • 2 Thus, following this approach, prostatic ductal lesions are derived from the large periurethral ducts, and the lesional cells tend to share their tall columnar morphology. (bmj.com)
  • An alternative approach makes a morphological analogy between prostatic ductal lesions and the in situ neoplasias of the breast. (bmj.com)
  • Medium magnification showing spindle cell sarcoma replacing and distorting prostatic tissue. (medscape.com)
  • PSA is highly specific for prostatic tissue. (cdc.gov)
  • Prostatic stromal sarcoma is a rare malignant neoplasm of mesenchymal origin that is believed to originate from specialized stromal prostatic cells. (medscape.com)
  • This image demonstrates a malignant spindle cell tumor replacing the prostatic stroma and invading vascular structures. (medscape.com)
  • Stromal sarcoma may arise de novo or coexist with either preexistent or concurrent prostatic stromal tumors of uncertain malignant potential (STUMP), suggesting a potential for STUMP in dedifferentiate into stromal sarcoma. (medscape.com)
  • [ 1 ] The World Health Organization (WHO) (also known as l'Organisation Mondiale de la Sante [OMS]) classification of prostatic stromal proliferations includes this tumor as a distinctive spindle cell neoplasm and categorizes them as STUMPs and stromal sarcomas. (medscape.com)
  • The true incidence of prostatic stromal sarcomas has not been established because of the rarity of this tumor. (medscape.com)